Deregulation of keratinocyte differentiation and activation: a hallmark of venous ulcers

Olivera Stojadinovic ^a, Irena Pastar ^a, Sasa Vukelic ^a, Mỹ G. Mahoney ^c, Donna Brennan ^c, Agata Krzyzanowska ^a, Michael Golinko ^b, Harold Brem ^b, Marjana Tomic-Canic ^{a, d} *

^a Hospital for Special Surgery of the Weill Cornell Medical College, Tissue Repair Lab, New York, NY, USA

^b Columbia University College of Physicians and Surgeons, Department of Surgery,

Wound Healing Program, New York, NY, USA

^c Department of Dermatology and Cutaneous Biology, Jefferson Medical College,

Thomas Jefferson University, Philadelphia, PA, USA

^d Department of Dermatology, Weill Cornell Medical College, New York, NY, USA

Received: December 6, 2007; Accepted: March 21, 2008

Abstract

Epidermal morphology of chronic wounds differs from that of normal epidermis. Biopsies of non-healing edges obtained from patients with venous ulcers show thick and hyperproliferative epidermis with mitosis present in suprabasal layers. This epidermis is also hyperkeratotic and parakeratotic. This suggests incomplete activation and differentiation of keratinocytes. To identify molecular changes that lead to pathogenic alterations in keratinocyte activation and differentiation pathways we isolated mRNA from non-healing edges deriving from venous ulcers patients and determined transcriptional profiles using Affymetrix chips. Obtained transcriptional profiles were compared to those from healthy, unwounded skin. As previously indicated by histology, we found deregulation of differentiation and activation markers. We also found differential regulation of signalling molecules that regulate these two processes. Early differentiation markers, keratins K1/K10 and a subset of small proline-rich proteins, along with the late differentiation marker filaggrin were suppressed, whereas late differentiation markers involucrin, transgultaminase 1 and another subset of small proline-rich proteins were induced in ulcers when compared to healthy skin. Surprisingly, desomosomal and tight junction components were also deregulated. Keratinocyte activation markers keratins K6/K16/K17 were induced. We conclude that keratinocytes at the non-healing edges of venous ulcers.

Key words: venous ulcers • chronic wounds • keratinocyte differentiation • keratinocyte activation • desmosomes • wound healing • transcriptional profiling • microarrays

Introduction

Chronic wounds, such as venous ulcers, affect hundreds of thousands of patients each year. They represent a serious healthcare problem around theworld. Venous ulcers develop as a consequence of venous valvular incompetence causing venous reflux, obstruction and subsequently venous hypertension. Their chronicity, frequent relapses and associated complications heavily impact patient's quality of life and increase healthcare costs.

Venous ulcers are responsible for more than half of lower extremity ulcerations, with prevalence ranging from 0.06% to 2% [1]. A rough estimate shows that the prevalence of unhealed venous ulcers is about 0.3%, that is about 1 in 350 adults [2], or approximately 400,000–600,000 cases in the United States [3]. Treatment of these ulcers sometimes requires numerous hospitalizations and treatment modalities incorporating topical dressings, antibiotics, debridement, compression therapy and cellular therapy. After wound healing with non-operative methods the incidence rate of recurrent ulcerations after 3 and 5 years was reported to be 37% and 48%, respectively [3].The annual cost of

^{*}Correspondence to: M. TOMIC-CANIC,

Hospital for Special Surgery, Weill Cornell Medical College, Tissue Repair Lab, Tissue Engineering, Regeneration and Repair Program, 535 E 70th Street, New York, NY, 10021. Tel.: +(212)-774-7160 Fax: +(212)-249-2373 E-mail: tomicm@hss.edu

the venous disease in the United States has been estimated between \$1.9 billion and \$2.5 billion [4], and in one retrospective cohort study the average total medical cost per patient was \$9685 (median: \$3036) [5]. Currently, only human skin equivalent is approved (for safety and efficacy) therapy in venous ulcers. [6]. Lack of understanding the biology at a cellular and molecular level is a barrier to creating further effective treatments.

Healthy epidermis provides a protective barrier that undergoes constant renewal. In this multi-layered, highly cellular tissue cell-to-cell connection occurs *via* desmosomes, adherens junctions, gap and tight junctions (TJs). TJs control paracellular permeability and maintain cell polarity, thus maintaining barrier function [7]. Basal keratinocytes divide and as they start differentiating and leaving the basal compartment they undergo changes in gene expression and commit to terminal differentiation resulting in formation of enucleated corneocytes. Once the barrier is broken, keratinocytes become activated in response to epidermal injury and start to proliferate, migrate and express a specific subset of keratin proteins suprabasally, keratins 6, 16 and 17 [8].

We have shown previously that skin deriving from the nonhealing edge of chronic ulcers (*e.g.* venous, pressure and diabetic foot ulcers) exhibits distinct morphology. The epidermis becomes hyperproliferative, hyper- and parakeratotic with the presence of mitoticaly active cells in suprabasal layers [9, 10]. We have also shown that activation of c-myc and nuclearization of β -catenin in the epidermis of patients with chronic wound play a role in inhibition of keratinocyte migration and contribute to impairment of healing in chronic wounds [9].These changes suggest inadequate execution of either of the two major processes important for epidermal maintenance and homeostasis: activation and differentiation.

To test if indeed these two processes are impaired in venous ulcers, we utilized large-scale microarray analyses and biopsies of non-healing edges of three patients suffering from venous ulcers. Microarray technology has brought the ability to simultaneously analyse the expression patterns of tens of thousands of genes and thereby identify groups of differentially regulated genes involved in pathogenesis of many different diseases. It has been used successfully in gene expression analyses of various tumours [11, 12] and wound healing of different tissues [13–18]. To the best of our knowledge a focused, large-scale microarray analysis has not been performed for patients with chronic wounds.

In this study, we compared expression profiles of patients' biopsies from non-healing edges of venous ulcers to profiles obtained from biopsies of healthy skin. Among 1557 genes that are differentially regulated in a statistically significant manner (P < 0.05), we particularly focused on groups of genes that characterize regulation of main biological processes in keratinocytes: activation and differentiation. We found keratinocyte activation markers to be induced. Proliferation is a component of keratinocyte activation. Cell cycle related genes, both cell cycle activators and repressors, were differentially regulated suggesting the loss of cell cycle control. Furthermore, we found deregulation of early and late differentiation markers, as well as regulators of keratinocyte differentiation, suggesting improper execution of either the early or late phase of differentiation. Microarray data were evaluated and confirmed using quantitative real-time PCR and immunohistochemistry.

We conclude that keratinocytes at the non-healing edges of venous ulcers are caught in a loop of trying to execute either of two processes, proliferation and differentiation, thus resulting in a thick hyperproliferative, hyper- and parakeratotic epidermis.

Materials and methods

Skin specimens used in study

Institutional review board approval was obtained and skin biopsies deriving from non-healing edges of venous ulcers were collected from normally discarded tissue after surgical debridement procedures on three consented patients with venous reflux ulcers in accordance with the Declaration of Helsinki Principles. Three healthy skin specimens were obtained as discarded tissue from reduction mammoplasty. As previously shown, three biological replicates are sufficient to generate valuable microarray analyses [19]. A portion of biopsies were embedded in tissue-freezing media (Triangle Biomedical Sciences, NC, USA) and frozen on dry ice, whereas the rest of the samples were stored in RNAlater (Ambion, Foster City, CA, USA) for the immediate RNA isolation. Prior to RNA isolation from skin specimens, tissue morphology was evaluated histologically and mixed cell population was addressed as previously described [10].

Debridement techniques of venous ulcers

Venous ulcers biopsies were obtained from normally discarded tissue from patients. All patients were debrided in the operating room under monitored anaesthesia care or general anaesthesia and in all cases local lidocaine injection was used for local anaesthesia. After the wound was prepped in betadine, a No. 20 sterile surgical scalpel was used to debide the flat wound edges. No undermining was encountered. The non-healing edges used in this study were clinically identified by a single surgeon (Dr. Brem) as the edge of the most proximal skin edge to the ulcer bed, often times indicated by the presence of callus. Multiple biopsies were taken of each patient within 30 min. of the injection of local anaesthetic. Once the samples were brought to the laboratory, routine histolpathological analysis with hemotoxylin & eosin were performed to verify typical morphology of the non-healing edge as described by Stojadinovic et al. [9]. Briefly, acanthotic epidermis with hyperkeratosis and parakeratosis are indicative of a nonhealing edge of the wound, in addition to presence of fibrosis. Furthermore, immunohistochemistry staining for makers of chronic wounds (c-myc and β-catenin) was performed and all samples stained positive. Only biopsies that fulfilled these two assays were used in the study.

Preparation and hybridization of probes

Samples were homogenized and total RNA was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Approximately 5 μ g of total RNA was reverse transcribed, amplified and labelled as described [20]. Labelled cRNA was hybridized to HG-U133A-set Gene Chip probe arrays that contain probe sets representing approximately

22,000 genes (Affymetrix, Santa Clara, CA, USA). The arrays were washed and stained with avidin-biotin streptavidin-phycoerythin labelled antibody using Affymetrix fluidics station and then scanned using the Agilent GeneArray Scanner system (Hewlett-Packard, Palo Alto, CA, USA) as described by Affymetrix.

Gene array data analysis

Microarray Suite 5.0 (Affymetrix) was used for data extraction and for further analysis, data mining tool 3.0 (Affymetrix, Santa Clara, CA, USA) and GeneSpring[™] software 7.3.1 (Silicon Genetics, Redwood City, CA, USA) were used for normalization to the median and filtration on the Volcano plot for degree of change and *P*-value calculations. Samples were normalized per chip: to the 50th percentile and per gene to a median. Statistical comparisons of expression level between each condition were performed using ANOVA test. Only genes with a P-value less than 0.05 were considered to be statistically significant. Differential expressions of transcripts were determined by calculating the degree of change. Genes were considered regulated if the expression levels differed more than 2-fold relative to healthy skin. Clustering was performed based on individual gene expression profiles. We developed an extensive gene annotation table describing the molecular function and biological category of the genes present on the chip as previously described [10]. The genes were annotated according to this table.

Immunohistochemistry

Slides containing frozen five micrometer thick skin sections were fixed in acetone (-20°C) for 1 min. Sections were blocked in 5% bovine serum albumin (BSA) and following primary antibodies diluted in 5% BSA/Phosphate Buffered Saline (PBS) were used: antibody against Filaggrin [21] and K10 (gift from Dr. H Sun, New York University), Involucrin (NeoMarkers, Fremont, CA, USA) and K17 (Gift from Dr. P. Coulombe, Johns Hopkins University) [22]. For staining with Dsg3, Dsc2 and DP, sections were permeabilized with 1%Triton-X-100 in PBS for 5 min., washed and blocked in 1% BSA/0.1% Triton X-100 in PBS for 1 hr at room temperature (RT). Sections were incubated with antibodies against desmocollin 2 (7G6), desmoglein 3 (5H10) and desmoplakin (23F4) (kind gift from Dr. James K Wahl III, University of Nebraska) overnight at +4°C. Signal was visualized using Alexa-Fluor 488 or 594 (Invitrogen, Carlsbad, CA, USA) secondary antibody. Slides were mounted with mounting medium containing 4',6-diamidino-2-phenylindole (DAPI) (Vector Labs, Burlingame, CA, USA). Staining was analysed using Nikon Eclipse E800 microscope and digital images were collected using SPOT-Camera Advanced program.

Quantitative real-time PCR analysis

For real-time PCR, 0.5 µg of total RNA from healthy skin and venous ulcer was reverse transcribed using a Omniscript Reverse Transcription kit (Qiagen, Valencia, CA, USA). Real-time PCR was performed in triplicate using the iCycler iQ thermal cycler and detection system and an iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). Relative expression was normalized for levels of HPRT1. The primer sequences used were: HPRT1, fw (5'-AAAGGACCCCACGAAGTGTT-3') and rev primer (5'-TCAAGGGCATATCCTACAACAA-3'); DEFB4, fw (5'-GGTGGTATAGGC- GATCCTGTT-3') and rev primer (5'-AGGGCAAAAGACTGGATGACA-3'); KLK6, fw (5'-CATGGCGGACCCCTGCGACAAGAC-3') and rev primer (5'-TGGATCACAGCCCGGACAACAGAA-3'); MMP11 fw (5'-AGATCTACTTC-TTCCGAGGC) and rev primer (5'-TTCCAGAGCCTTCACCTTCA-3'); CCL27 fw (5'-TCCTGAGCCCAGACCCTAC-3') and rev primer (5'-CAGTTCCACCTG-GATGACCTT-3'); APOD fw (5'-AATCAAATCGAAGGTGAAGCCA) and rev primer (5'-ACGAGGGCATAGTTCTCATAGT-3'); S100A7 fw (5'-GGAGAACT-TCCCCAACTTCC-3') and rev primer (5'-ACATCGGCGAGGTAATTTGT-3'); BMP2 fw (5'-TCAAGCCAAACAACAAACAGC-3') and rev primer (5'-GTG-GCAGTAAAAGGCGTGAT-3'); BMP7 fw (5'-AGGCCTGTAAGAAGCACGAG-3') and rev primer (5'-GGTGGCGTTCATGTAGGAGT-3'); K17 fw (5'-GGTGGG-TGGTGAGATCAATGT-3') and rev (5'- CGCGGTTCAGTTCCTCTGTC). Statistical comparisons of expression levels were performed using Student's t-test.

Results

To determine genes that play a role in pathogenesis of venous ulcers we performed microarray analysis, utilizing biopsies from non-healing edges of venous ulcers from three patients with venous stasis ulcers and three healthy skin specimens. All three patients presented with an ulcer on a lower left leg, longer than an year in duration (Fig. 1). Proper diagnosis was made following previously published guidelines and protocols [3, 23]. Evaluation for ischaemia was performed either by non-invasive flow exams (ankle-brachial index of <0.9) or by arteriogram. All patients did not have evidence of ischaemia. In addition, all patients had a venous duplex exam and confirmed the presence of venous valvular incompetence and venous reflux. None of the patients had diabetes. All patients had haemosiderosis upon clinical exam.

To compare gene expression profiles from obtained skin specimens, we performed cluster analyses using GeneSpring[™] 7.3.1 software. We generated a gene tree employing all genes present on the chip and visualized the expression profile of each sample (Fig. 2). As expected, skin specimens obtained from healthy, control skin were clustered together separate from cluster of skin specimens obtained from venous biopsies, thus confirming differential gene expression profiles derived from venous ulcers *versus* healthy skin.

Overall microarray data analyses

When the gene expression profile of skin derived from edges of non-healing wounds was compared to healthy skin, a differential expression of transcripts was determined by calculating the degree of change. Genes were considered regulated if the expression levels differed more than 2-fold relative to healthy skin. Duplicates were eliminated and genes of unknown function were excluded. Of approximately 22,000 genes presented on the chip, we found 1557 genes to be differentially regulated between non-healing edges of venous ulcers and healthy skin. Out of 1557 genes, 55% of genes were down-regulated and



Fig. 1 An image of a venous ulcer used in this study. The arrow is pointing to the location of a non-healing edge from which biopsy for microarray analysis was obtained.

45% were up-regulated. We sorted regulated genes according to their biological functions, *i.e.* process in which they participate (Fig. 3). Furthermore, we selected the top 50 up-regulated and the top 50 down-regulated genes based on the degree of change and *P*-values (P < 0.05) and grouped them by cellular functions and biological processes (Fig. 4). The most regulated genes fell into following biological processes: contact and motility, tissue remodelling, inflammation and immunity, proliferation, differentiation, cell death control, metabolism and signal transduction and transcription. To better understand molecular changes in non-healing edges of venous ulcers we focused on specific cellular functions and processes affected by venous ulcer environment.

Keratinocyte activation markers

Activation of keratinocytes is marked by the induction of a specific set of keratins: keratins 6, 16 and 17. We have shown previously induction of K6 at the non-healing edges of chronic wounds [9]. Microarray data confirmed induction of keratin 6 (K6). In addition, induction of keratin 16 (K16) was also found in venous ulcers. Interestingly, we could not detect keratin 17 (K17), another keratinocyte activation marker, among genes regulated more than 2-folds. We checked generated gene list of statistically regulated genes before we made the 2-folds cut-off, and found K17 among



Fig. 2 Gene tree showing different gene expression patterns between venous ulcers (left) and healthy skin (right).

up-regulated genes. K17 expression was induced 1.86-fold. To confirm changes in K17 expression we performed real-time PCR and found K17 induced in non-healing edges of venous ulcers as compared to normal skin (Fig. 5A). Furthermore, we used K17-specific antibody to stain healthy skin and skin biopsies harvested form venous ulcers. As expected, healthy epidermis does not show K17 staining, whereas epidermis from non-healing edge of venous ulcers shows robust signal (Fig. 5B). Therefore, keratinocytes at the non-healing edge of venous ulcers express early activation markers.

Keratinocyte activation: proliferation

Keratinocyte proliferation is one of the cellular processes defining keratinocyte activation. Hyperproliferation of keratinocytes is characteristic of the epidermis of the non-healing edge. Interestingly, our microarray analyses show deregulation of cell cycle associated genes. In mammalian cells, a crucial checkpoint control for proliferation is provided by the pocket proteins of the retinoblastoma (Rb) family [24, 25]. All three pocket proteins of the Rb family, Rb, p107 and p130 were found down-regulated in

52%	Adhesion	48%	
60%	Antioxidants	40%	
53%	Apoptosis	40 /4	Up- regulated genes
20%	Cabinding	4/76	→
47%	Cell cycle	521/	Down- regulated genes
83%	Cell growth, proliferation	17%	
75%	Cytohrome	25%	
59%	Cytoskeletal	41%	
29%	Detoxification	71%	
80%	Development	20%	
80%	DNA binding	20%	
45%	DNA repair, synthesis	55%	
45%	ECM	55%	
23%	Energy	77%	
42%	Enzyme	58%	
13%	Epidermal differentiation	87%	
47%	Golgi apparatus	53%	
54%	G- regulated protein	46%	
67%	Heat shock	33%	
47%	Immune response related	53%	
8%	Immunoglobulin	92%	
67%	INF- regulated	33%	
44%	Membrane protein	56%	
38%	Membrane, cell surface	62%	
38%	Metabolism	62%	
27%	Mitochondrial	73%	
86%	Nuclear receptors	14%	
54%	Nucleoskeletal	46%	
67%	Oncogenesis	33%	
46%	Proteolysis	54%	
64%	Phosphatase	36%	
80%	Protein binding	20%	
53%	Protein kinase	47%	
33%	Protein, inhibitor	67%	
18%	Protein modification	82%	
58%	Receptors	42%	
58%	Regulators	42%	
85%	RNA metabolism	15%	
63%	Secreted	37%	
63%	Signal transduction	37%	
58%	Trafficking	42%	
70%	Transcription	30%	
79%	Transcription factor	21%	
83%	Transcription repressor	17%	
70%	Translation	30%	
47%	Transporter	53%	
73%	Tumor antigen	27%	

Fig. 3 Percentage of genes differentially regulated between non-healing edges of venous ulcers and healthy skin samples sorted according to biological functions.

our microarray data, suggesting loss of cell cycle control. Furthermore, cyclin B1, cyclin D2, cyclin A2, cyclin F and cyclin M4 were up-regulated along with cell division cycle 2 (CDC2) suggesting an increase of CDC2/cyclin B1 and CDC2/cyclin A2 complexes, promoting both cell cycle G1/S and G2/M transitions. In contrast, cyclin D1 and eukaryotic translation initiation factor 4E (EIF4E) which promotes the nuclear export of cyclin D1, were found down-regulated in non-healing edges. Microarray analyses further show a loss of cell cycle checkpoint regulation. Checkpoint suppressor 1 (CHES1) and Wee1-like protein kinase (WEE1) were down-regulated. WEE1 catalyses the inhibitory tyrosine phosphorylation of CDC2/cyclinB kinase and appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from cytoplasmically activated CDC2 kinase. Since both CDC2 and cyclin B1 were up-regulated coupled with loss of inhibitory phosphorylation by WEE1, we propose that this might account for the hyperproliferative phenotype in non-healing edges of venous ulcers. Two cyclin-dependent kinase inhibitors, Α

FC - P-value SVMBOL Unigene Comment FC 000 Trist Terror protein p53 inducible protein 3 Pro- apoptotic G6 003 BMP3 BCL2/Jadenovins E1B 19kD3 interracting protein 3 Anti - apoptotic G2 010 BEAD 2011 AP reparts containing 5 (survivi) Anti - apoptotic G2 011 BEAD 2011 AP reparts containing 5 (survivi) Anti - apoptotic G2 012 THFAIPD Lipid G3 013 BEAD 2010 APAP4 Taty acid binding protein 7, Varia G3 000 CRCPAS cyclothy A, member 2 G3 001 CYCPAS cyclothy A, and Apoptentia G3 001 CYCPAS cyclothrone Preceptor membrane component 2 G3 001 CYCPAS cyclothrone Preceptor phylopsitide 1, pre-B-cell specifie Carbohydrate G3 001 CYCPAS cyclothrone theorealismin Tornsport G3 001 CYCAS splicing factor prolineglutamine rich 2-RNA metabolism Metabolism G3 00100	•			
8.74 0.00 TF5313 tumor protein p53 inducible protein 3 } Pro-apoptotic 7.83 0.00 FMRS BCL2dedowins EIS Hobbs interacting protein 3 Anti - apoptotic 7.83 0.00 FABP7 fst1 action frame Anti - apoptotic 7.83 0.00 FABP7 fst1 action frame Anti - apoptotic 7.83 0.00 FABP7 fst1 action frame Anti - apoptotic 7.83 0.00 FABP7 fst1 action frame Anti - apoptotic 7.83 0.00 FABP7 fst1 action frame Anti - apoptotic 7.83 0.00 FABP7 fst1 action frame Anti - apoptotic 7.83 0.00 FABP7 fst1 action frame Anti - apoptotic 7.83 0.00 FABP7 fst1 action frame Anti - apoptotic 7.83 0.00 CAT Cytochrome #430, family 3, automity A, Anti - apoptotic Anti - apoptotic 7.83 0.00 CAT Cytochrome #430, family 3, automity A, Anti - apoptotic Anti - apoptotic 7.83 0.00 CAT Cytochrome #430, family 3, automity A, Anti - apoptotic Anti - apoptotic <	FC P-value	SYMBOL	Unigene Comment	
633 0.01 BIRCS baculoviral LAP repeat-containing 5 (survivin) Anti - apoptotic Cell Death Control 633 0.00 SCGB102 secretoplobin, family 10, member 2 Lipid 633 0.00 SCGB202 secretoplobin, family 2A, member 2 Lipid 634 0.00 SCGB202 secretoplobin, family 2A, member 2 Steroid 634 0.00 SCGB202 secretoplobin, family 2A, member 2 Antino acid 635 0.00 FXVI Kynurenines (L-Kynurenine type) Antino acid 635 0.01 CVP3A5 glutathione peroxidase if Antino acid 635 0.01 CRX1 glutathione peroxidase if Other 635 0.01 CRX1 glutathione peroxidase if Other Transport 635 0.01 CRA145 UPA-vacetyl-aphen 2-adiactosamine Other Transport 635 0.01 CRA145 upA-vacetyl-aphen 2-adiactosamine Transport Transport 73.50 0.01 CRA145 upA-vacetyl-aphen 2-adiactosamine Transport Transport 73.50 0.01 CRA145	8.74 0.00 6.61 0.03	TP53I3 BNIP3	tumor protein p53 inducible protein 3 BCL2/adenovirus E1B 19kDa interacting protein 3 Pro- apoptotic	
22 2 102 ThFAIP3 tumor necress lactor, apha-induced protein 3 J 22 3 000 FABP2 text protein 4, adipocyte Lipid 3 100 FABP4 fatty acid binding protein 4, adipocyte Lipid 3 100 FABP4 fatty acid binding protein 4, adipocyte Janico acid 4 30 005 CLU clusterin Anio acid 5 000 FABP4 fatty acid binding protein 4, adipocyte Janico acid 6 001 CO2 tryptopina 2,3-diozygenase Janico acid Janico acid 6 001 CAYT glutathione peroxidase 7 Other Other 6 001 CAYT glutathione peroxidase 7 Other Other 6 001 CAYT glutathione peroxidase 7 Other Other 6 001 CAYT glutathione peroxidase 7 Other Transport 6 013 GAYA GAYA	6.32 0.01	BIRC5	baculoviral IAP repeat-containing 5 (survivin)] Anti - apoptotic	Cell Death Control
23:30 ChaPP / Entry acid binding protein 4, adipocyte / Lipid 51:30:00 FABP4 / Entry acid binding protein 4, adipocyte / California a science / California / Californi / Califori / California / Califori / Califori / Califor	-22.62 0.02	TNFAIP3	tumor necrosis factor, alpha-induced protein 3	
4.31 Color FABP4 fatty socid binding protein 4, adipocyte] Lipid 588 0.00 FCBL/2 protein 4, adipocyte] Steroid 4.33 0.00 FCBL/2 progesterone receptor membrane component 2 Steroid 507 0.00 FCBL/2 progesterone receptor membrane component 2 Steroid 507 0.00 FCBL/2 progesterone receptor membrane component 2 Steroid 507 0.00 FCBL/2 progesterone receptor membrane component 2 Steroid 507 0.00 FCBL/2 progesterone receptor membrane component 2 Maino acid 507 0.00 FCBL/2 progesterone receptor membrane component 2 Other 508 0.00 FCRL glip autoantige monocxygenase 3 Other 517 0.00 FCLAR glip autoantige fullaminin a chi 2 Other 513 0.00 FCLAR glip autoantige fullaminin a chi 2 Other 513 0.00 FCLAR GLEAR FCLAR FCLAR 513 0.00 GLEAR GLEAR FLEAR FCLAR 513 <	-59.88 0.00	SCGB1D2	fatty acid binding protein 7 brain	`
53:88 0.00 SCGB2A2 secretogiobin, family 2A, membare component 2 Steroid 43:00.00 PGRMC2 progesterone receptor membrane component 2 Steroid 43:00.00 PGRMC2 progesterone receptor membrane component 2 Amino acid 43:00.00 PGRMC2 tryptophan 3.2-dioxygenase Amino acid 60:00 LC212 typtophan 3.2-dioxygenase Amino acid 60:00 FGRMC3 fixit containing monocxygenase 3 Other 60:01 GPX glutathione peroxidase 7 Other 70:00:00 GOG GAA opgin subfamily 1, member 3 Attrasport 71:00:00 GPX splicing factor prolineglutamine rich 2-RN metabolism Transport 71:00:00 GPX alcohol dehydrogenase 4 family 1, member 3 Energy 71:00:02 CPA3 alcohol dehydrogenase 4 family member 4 Energy 71:00:02 CPA3 famile fastro famine social symponein Factors <td>-8.13 0.00</td> <td>FABP4</td> <td>fatty acid binding protein 4, adipocyte</td> <td></td>	-8.13 0.00	FABP4	fatty acid binding protein 4, adipocyte	
14.33 0.05 CLU clusterin Clusterin Storoid 3.20 0.00 CYR0AD cytochrome P400, family 3, subfamily A, polypeptide 5 Storoid 3.00 0.01 CYR0AD cytochrome P400, family 3, subfamily A, polypeptide 5 Amino acid 3.01 0.00 LOC2 typy loxidase-like 2 Amino acid 3.70 0.00 LOC31316 immunoglobulin lambda-like polypeptide 1, pre-B-cell specific Carbohydrate 3.70 0.00 COC31316 immunoglobulin lambda-like polypeptide 1, pre-B-cell specific Carbohydrate 3.70 0.00 COC31316 immunoglobulin lambda-like polypeptide 1, pre-B-cell specific Carbohydrate 3.70 0.01 CRA autoantigenologin autoantigenologin autofamino acid symporter), member 1 Transport 17.83 0.00 TCN transcobalamin 1 Storoid Symporter), member 31 Energy 3.30 0.01 TCR transcobalamin 1 Storoid Symporter), member 1 Transport 18.33 0.01 TCR transcoroid autoantigenologin autoantig	-59.88 0.00	SCGB2A2	secretoglobin, family 2A, member 2	
-8.20 0.00 PGKML2 progresterone receptor membrane component 2 Steroid 0.00 0.00 CVM3 cytonome P4G, multy 3, ubinomity 4, polypeptide 5 Amino acid 0.00 0.04 TDO2 typtophan 3,-dioxygenase ytrolese Amino acid 0.01 0.02 1/yi otdase-like 2 Amino acid Amino acid 0.01 0.02 1/yi otdase-like 2 Amino acid Other 0.01 0.02 0.01 0.01 Carbohydrate 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01	-14.39 0.05	CLU	clusterin	
3.40 0.00 CYRMA CyrMany Section on Pack, family 3, subramily A, polypeptide 5.3 9.10 0.00 CO2 typy loxidase-like 2 9.10 0.00 CO23136 immunoglobulin lambda-like polypeptide 1, pre-B-cell specific Carbohydrate 9.17 0.00 CO23136 immunoglobulin lambda-like polypeptide 1, pre-B-cell specific Carbohydrate 9.17 0.00 CO23136 immunoglobulin lambda-like polypeptide 1, pre-B-cell specific Carbohydrate 9.18 0.00 CR diatatione perceidiase 7 Other Other 9.18 0.00 CR diatatione perceidiase 7 Other Other 9.18 0.00 CR automingen, golgin subfamily a, 4 Other Other 9.18 0.00 CR solute carrier family 2, member 3 Carbohydrate Famperitie 9.18 solute carrier family 3.6 (protonlamino acid symporter), member 1 Transport Famperitie 10.30 0.00 ART810 aldoc keto reductase family 1, member 810 (aldose reductase) Energy 47.10 0.02 KR1810 aldoc keto reductase family 1, member 810 (aldose reductase) Energy	-8.20 0.00	PGRMC2	progesterone receptor membrane component 2	
8:08 1002 tryptophan 2,3-dickygenase Amino acid 9:11 0.00 LOXL2 typy loxidase-like 2 Amino acid 9:12 0.00 LOXL2 typy loxidase-like 2 Amino acid 9:13 0.00 LOXL2 typy loxidase-like 2 Amino acid 9:13 0.00 LOXL2 typy loxidase-like 2 Amino acid 9:03 0.00 LOXL2 typy loxidase-like 2 Other 9:03 0.00 CALNTS UDP-N-acetyl-alpha-D-galactosamine Other 9:03 0.00 CALNTS UDP-N-acetyl-alpha-D-galactosamine Transport 9:03 0.00 CALSAL transferrin receptor (p80, CD71) Transport 9:03 0.00 AKR1B70 aldo-keto reductase family 1, member B10 (aldose reductase) Energy 9:03 0.00 AKR1B70 aldo-keto reductase family 1, member B10 (aldose reductase) Energy 9:03 0.00 AKR1B70 aldo-keto reductase family 1, member B10 (aldose reductase) Energy 9:04 0.01 ZAFE thight protein 36, C3H type-like 14 Transcription Facor 9:03 <td< td=""><td>8.00 0.01</td><td>KYNU</td><td>kynureninase (I -kynurenine hydrolase)</td><td></td></td<>	8.00 0.01	KYNU	kynureninase (I -kynurenine hydrolase)	
9.15 0.00 LOXL2 lyśył oxidase-like 2 ⁻⁰ June Colling (Carbohydrate delodinase, idodfhyronine, type II Colling (Carbohydrate delodinase) (Carbohydrate delodinase, idodfhyronine, type II Carbohydrate delodinase, idodfhyronine, idodfhyronine, type II Carbohydrate delodinase, idodfhyronine, idodfhyronine, idodfhyronine, idodfhyronine, idodfhyronine, idodfhyronine, idodfhyr	8.09 0.04	TDO2	tryptophan 2.3-dioxygenase	
18.27 0.00 LOC91316 immunoglobulin lambda.ike polypeptide 1, pre-B-cell specific? Carbohydrate 0.00 CO2444 glutathione peroxidase 7 other 0.01 CPX7 glutathione peroxidase 7 other 0.02 GALNTS UDP-N-acetyl-alpha-D-galactosamine other 0.03 GOTAH glutathione peroxidase 7 other 0.04 GOTAH glutathione peroxidase 7 other 0.05 GOTAH glutathione peroxidase 7 other 0.05 GOTAH glutathione peroxidase 7 other 0.07 GOTAH glutathione of Alpha-D-galactosamine other 0.07 GOTAH glutathione containing and the peroperoxidase 7 other 0.08 GOTAH GOTAH glutathione containing and the peroperoxidase 7 formatione and deperoperoxidase 7 0.08 GOTAH GOTAH Bloba 10 formatione and deperoxidase 7 formatione and depe	9.15 0.00	LOXL2	lysyl oxidase-like 2	
776 010 D23448 Metaboons according gene year Metabolism 0.06 0.01 GRX r gluattathore percevidase 7 Other 0.66 0.01 FMO3 flavin containing monoxygenase 3 Other 0.67 0.00 GCLGA4 ogli autoantigen, odgin subfamily a, 4 Other 0.76 0.00 GCLGA4 ogli autoantigen, odgin subfamily a, 4 Transcobalamin 0.76 0.00 GCLGA4 ogli autoantigen, odgin subfamily a, 4 Transcobalamin 0.76 0.00 SLC36A1 solute carrier family 36 (proton/amino acid symporter), member 1 Transport 0.77 0.00 SLC36A1 solute carrier family 36 (proton/amino acid symporter), member 1 Transport 0.78 0.00 ATA binding protein 3 Y, member 10 (alcose reductase) Energy 0.74 0.01 GATA binding 4 Transcription Factors Factors 0.74 0.02 SCA7 spinocerebellar ataxia 7 Transcription Factors Factors 1.75 0.02 SCA7 spinocerebellar ataxia 7 Transcription Factors Factors <	18.27 0.00	LOC91316	immunoglobulin lambda-like polypeptide 1, pre-B-cell specific Carbonydrate	
6.00 CPX7 glutathione peroxidase 7 6.65 0.01 CPX7 glutathione peroxidase 7 6.65 0.01 CPX1 transcobalamin 1 6.75 0.00 COL1 transcobalamin 1 7.87 0.00 GOLGAA golgi autoantigen, golgin subfamily a, 4 7.87 0.00 SPCA splicing factor proline/glutamine rch 2 RNA metabolism 7.87 0.01 SPCA splicing factor proline/glutamine rch 2 RNA metabolism 7.83 0.00 REL3 transferrin receptor (90) CD711 7.87 0.00 REL4ike 2 aldehyde dehydrogenase 1B (class 1), beta polypeptide Finansport 7.83 0.00 ALDH4A1 aldehyde dehydrogenase 1B (class 1), beta polypeptide Finansport 7.83 0.00 ALDH4A1 aldehyde dehydrogenase 1B (class 1), beta polypeptide Finansport 7.84 0.01 FOSB FEJ mutrine osteosarcoma viral oncogene homolog B Finansport 7.42 0.01 FOA MAFF Y-mat musculoaponeurotic fibrosarcoma oncogene homolog F Factors 7.72 MAFF Y-mat muscoponeurotic fibrosarcom	7.70 0.00	D2S448	Melanoma associated gene	➢ Metabolism
6.66 0.011 FMO3 flavin containing monoxygenase 3 COther 6.56 0.00 CALNT6 UPN-Nacetyl-alpha-D-galactosamine 7.10 0.00 GGLGA4 golg autoantigen, golg in subfamily a, 4 8.71 0.00 GGLGA4 golg autoantigen, golg in subfamily a, 4 8.71 0.00 SPEQ. splicing factor proline/gultamine rich - P.RNA metabolism 8.71 0.00 SLC36A1 splicing factor proline/gultamine rich - P.RNA metabolism 8.73 0.01 FREC resterior (g00_GC71) 7.83 0.00 SLC36A1 solute carrier family 36 (proton/amino acid symporter), member 1 7.83 0.01 AKR1B10 alcohol dehydrogenase 18 (class l), beta polypeptide 9.80 0.00 AKR1B10 alcohol dehydrogenase 14 (proton/amino acid symporter), member 1 7.81 0.01 CATA3 GAT Ab Inding protein 3 fcatricohydrogenase 18 (class l), beta polypeptide 9.80 0.00 AKR1B10 alcohol dehydrogenase 14 (proton/amino acid symporter) Fnergy 7.41 0.02 CATA3 GAT binding protein 36 GAT type-Iwhe factor 3 7.41 0.02 CATA3 <td>6.09 0.01</td> <td>GPX7</td> <td>glutathione peroxidase 7</td> <td>(</td>	6.09 0.01	GPX7	glutathione peroxidase 7	(
8.54 0.02 CALNIE UDP-N-acetyl-algnat-Degalactosamine 9.77 0.00 GPLOA golgi autoantigen, golgi autoantigen	6.65 0.01	FMO3	flavin containing monooxygenase 3 > Other	
335 1000 Cort columnation Total of SPO2 Selicing factor proline glutamine rich 2 RNA metabolism 108 0.03 SLC2A3 solute carrier family 2, member 3 Total of SPO2 Solute carrier family 36 (proton/amino acid symporter), member 1 Transport 6.35 0.01 SLC3A1 solute carrier family 36 (proton/amino acid symporter), member 1 Transport 6.35 0.00 SLC3A1 solute carrier family 36 (proton/amino acid symporter), member 1 Transport 6.36 0.00 AKR1810 aldo-keto reductase family 1, member A1 Energy 9.00 0.01 AKR1810 aldo-keto reductase family 1, member B10 (aldose reductase) Energy 9.01 0.01 AKR1810 aldo-keto reductase family 1, member B10 (aldose reductase) Energy 9.02 0.01 DAK KE2 Kruppel-like factor 2 (lung) Energy 11.10 DAK KE2 Kruppel-like factor 2 (lung) Energy 12.25 0.02 CFP3 (DAK Ker 2 (Lung) Energy 13.66 0.02 FER2 period homolog 2 Energy 13.61 0.02 FF3 Sp3 transcription factor Factors	8.54 0.02	GALN16	UDP-N-acetyl-alpha-D-galactosamine	
3.710 0.00 SFPO splicing factor profine/glutamine rich "> FNA metabolism 0.83 0.03 SLC2A3 solute carrier family 2, member 3 -3.33 0.01 TFRC transferrin receptor (p90, CD71) 6.36 0.00 SLC3A3 solute carrier family 3 6 (proton/amino acid symporter), member 1 13.76 0.00 NELL2 NEL-like 2 3.63 0.00 ALDHAA1 aldehyde dehydrogenase B (class I), beta polypeptide 3.78 0.00 ALDHAA1 aldehyde dehydrogenase B (class I), beta polypeptide 3.78 0.00 ALDHAA1 aldehyde dehydrogenase B (class I), beta polypeptide 3.78 0.00 ALDHAA1 aldehyde dehydrogenase A family, member A1 Energy 3.71 0.01 FATA bhinding protein 3 for aldehyde dehydrogenase A family, member A1 Energy 3.71 0.02 ZFP36L1 zinc finger protein 36, C3H type-like 1 for aldehydrogenase B (class I), beta polypeptide Energy 3.72 0.02 SCA7 spinocerebelia ratxia 7 for aldehydrogenase B (class I), beta polypeptide Energy 3.72 0.03 KLF2 KLF4 Kruppel-like factor 4	-8 77 0.00	GOLGA4	alaiscobalainin i	
 10.83 0.03 SLC2A3 solute carrier family 2, "member 3 5.30 0.01 TFRC transferrin receptor (p90, CD71) 6.35 0.00 SLC36A1 solute carrier family 36 (proton/amino acid symporter), member 1] Transport 7.8 0.00 NELL2 NELL4 NE 2 8.9 0.00 ALDHAA1 alcohyd dehydrogenase IB (class I), beta polypeptide 3.0 0.00 AKR1810 aldo-keto reductase family 1, member A1 1.0 0.00 AKR1810 aldo-keto reductase family 1, member B10 (aldose reductase) 9.00 0.00 AKR1810 aldo-keto reductase family 1, member B10 (aldose reductase) 9.01 0.01 AKR1810 aldo-keto reductase family 1, member A1 1.0 0.00 AKR1810 aldo-keto reductase family 1, member B10 (aldose reductase) 9.01 0.01 AKR1810 aldo-keto reductase family 1, member A1 1.0 0.02 ZFP36L1 inc finger protein 36, C3H type-like 1 9.02 0.02 THEG TGFB inducible early growth response 1.0 0.02 SCA7 spinocerebellar ataxia 7 12.72 0.02 KLF4 Kruppel-like factor 4 1.275 0.00 EGR3 early growth response 3 1.171 0.02 FER2 9.00 CGR3 early growth response 3 11.71 0.02 KLF5 Kruppel-like factor 5 9.26 0.02 SP3 Sp3 transcription factor 1 9.26 0.02 SP3 Sp3 transcription factor 1 1.12 0.02 ZFP36 zince finger protein 36, C3H type, homolog 7.81 0.01 NFIB nuclear factor IVB 1.15 0.01 CD44 attivating transcription factor 3 1.15 0.00 ZFP36 zinc finger protein 36, C3H type, homolog 7.88 0.00 ZHF451 zinc finger protein 36, C3H type, homolog 7.81 0.01 PGR2 odd-skipped-related 2A protein 7.81 0.01 PGR2 odd-skipped-related 2A protein 7.81 0.01 TGFR8 transcription factor 3 7.81 0.01 TGFR8 transcription factor 3 7.81 0.01 TGFR8 transcription factor 1 7.81 0.01 TGFR8 transcription factor 1 7.81 0.01 TGFR8 transforming growth factor, beta receptor III 7.81 0.01 TGFR8 transforming growth factor, fuencer 1 7.81 0.01 TGFR8 transforming growth factor, bet	-8.70 0.00	SFPQ	splicing factor proline/glutamine rich C RNA metabolism	
 4.3.9 U/1 IFKC, transferrin receptor (p9U, CD/1) 6.3.9 U/0 SLC3AAI solute carrier family 36 (protonlamino acid symporter), member 1 7.8 O/0 NELL2 NEL-like 2 8.0 Cl3AAI achold ethydrogenase IB (class I), beta polypeptide 9.00 O/A KHPI81 aldehydrogenase 4 family, member A1 9.01 O/A KHPI81 aldehydrogenase 4 family, member A1 9.02 O/A KHPI81 aldehydrogenase 4 family, member A1 9.03 O/A KHPI81 aldehydrogenase 4 family, member A1 9.04 O/A KHPI81 aldehydrogenase 4 family, member A1 9.05 O/A KHPI81 aldehydrogenase 4 family, member A1 9.06 O/A KHPI81 aldehydrogenase 4 family, member A1 9.07 O/A KHPI81 aldehydrogenase 4 family, member A1 9.08 O/A KHPI81 aldehydrogenase 4 family, member A1 9.09 O/A KHPI81 aldehydrogenase 4 family, member A1 9.00 AKHPI81 aldehydrogenase 4 family, member A1 9.01 D/A trinhibtor of D/A binding 4 4.71 O/2 ZFP36L1 zinc finger protein 36, C3H type-like 1 9.02 SCAF spinocerabellar atala 7 9.03 KLF2 Kruppel-like factor 2 (lung) 9.02 SCAF spinocerabellar atala 7 9.02 SCAF spinocerabellar atala 7 9.03 U/K KLF5 Gruppel-like factor 4 9.26 O/2 SCAF spinocerabellar atala 7 9.27 O/2 KLF5 Gruppel-like factor 4 9.26 O/2 SCAF spinocerabellar atala 7 9.27 O/2 KLF5 Gruppel-like factor 6 9.27 O/2 KLF5 Gruppel-like factor 6 9.27 O/2 KLF5 Gruppel-like factor 7 9.43 O/1 JUND Jun D proto-oncogene 9.43 O/1 JUND Jun D proto-incogene 9.44 D/1 KL aldehydrogen aldehydrogen aldehydrogene 9.44 D/1 KL aldehydrogen aldehydrogene 9.45 O/2 KLF5 Gruppel-like factor 7 9.47 O/2 ZFP36 transcription factor 8 9.47 O/2 ZFP36 transcription factor 8 9.48 O/3 SR2 dd+skiped-related 2A protein 9.43 O/3 OSR2 dd+skiped-related 2A protein factor 1/A 9.44 O/3 SR24 dd+skiped-related 2A protein factor 1/A<!--</td--><td>-10.83 0.03</td><td>SLC2A3</td><td>solute carrier family 2, member 3</td><td></td>	-10.83 0.03	SLC2A3	solute carrier family 2, member 3	
 Sector State is a sector in the sector is a procession of a class in poly particle is a polypeptide is a class of a class in polypeptide is a class of a cl	-8.33 0.01	IFRC SLC36A1	transterrin receptor (p90, CD71)	
 63.65 0.04 ADH1B alcohol dehydrogenase IB (class I), beta polypeptide 595 0.00 ALDH4A1 aldehyde dehydrogenase 4 family, member A1 70.00 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase). 70.01 GATA3 70.02 ZFP36L1 zinc finger protein 3 70.02 ZFP36L1 zinc finger protein 36, C3H type-like 1 70.03 KLF2 Kruppel-like factor 2 (lung) 70.03 KLF2 Kruppel-like factor 2 (lung) 70.03 KLF2 Kruppel-like factor 4 71.70 0.02 KLF3 Kruppel-like factor 4 72.70 0.02 KLF4 Kruppel-like factor 4 72.70 0.02 KLF3 Kruppel-like factor 4 73.80 0.01 FGR and the factor 5 oncogene homolog 74.71 0.02 ZFP36L1 zinc finger protein 36, C3H type, homolog 77.70 0.02 KLF3 Kruppel-like factor 7 70.70 0.02 KLF4 Kruppel-like factor 7 71.70 0.02 KLF3 Kruppel-like factor 7 72.70 0.02 KLF3 Kruppel-like factor 7 73.60 0.01 FGR and the response 1 74.70 0.00 NFB unclear factor file 74.71 0.02 ZFP36L zinc finger protein 36, C3H type, homolog 74.71 0.02 ZFP36 zinc finger protein 36, C3H type, homolog 74.71 0.04 BA21A bomodomain adjactor 1 75.10 0.01 CD44 CD44 antigen 76.22 GP12 ZFP36 zinc finger protein 36, C3H type, homolog 71.71 0.02 ZFP36 zinc finger protein 36, C3H type, homolog 71.71 0.02 ZFP36 zinc finger protein 36, C3H type, homolog 71.71 0.03 SF2 dod-skiped-related 2A protein 71.71 0.03 CR2 dod-skiped-related 2A protein 71.71 0.03 CR2 dod-skiped-related 2A protein 71.71 0.03 CR4 72.71 0.03 CR4 73.71 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 73.71 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 1 73.80 0.01 CF8 transcription factor 1A 74.80 0.01 CF8 75.90 C12 FR83 transcription factor 1A 76.90 C12 FR83 transcription factor 1A 76.90 C12 FR83 transcription factor 1A<	13.79 0.00	NELL2	NEL-like 2)
 9.95 0.00 ALDHA41 aldehyde dehydrogenase 4 family, member A1 9.95 0.00 AKR1810 9.87 0.01 GATA3 9.87 0.02 GATA binding 4 9.87 0.02 GATA binding 6 9.87 0.02 GATA 9.80 0.02 TEGA3 9.87 0.04 GATA 9.80 0.02 GATA 9.80 0.03 JUN 9.91 0.00 V-jun sarcoma virus 17 oncogene homolog 9.82 0.02 PER2 9.80 0.03 JUN 9.92 0.02 SP3 9.93 transcription factor 5 9.43 0.01 JUND jun D proto-oncogene 9.26 0.02 SP3 9.93 transcription factor 3 9.82 1.01 DATA 9.82 0.01 SF1 splicing factor 1 9.82 0.01 ZIF436 9.81 chickingen 9.82 0.01 ZIF436 9.82 1.01 Finger protein 36, C3H type, homolog 9.82 0.01 ZIF436 9.83 0.00 ZIF4361 9.81 chickingen 9.83 0.00 ZIF4361 9.84 0.01 AFF3 9.84 0.01 SIF45 9.82 0.01 SIF45 9.82 0.01 SIF45 9.82 0.01 SIF45 9.83 0.00 SIF2 9.83 transcription factor 3 9.84 0.01 AFF3 9.84 0.01 AFF3 9.84 0.01 SIF45 9.85 0.03 SF1 9.85 0.04 SIF45 9.85 0.04	-63.69 0.04	ADH1B	alcohol dehydrogenase IB (class I), beta polypeptide	
91.00 AKK1B10 aldo-keto reductase tamily 1, member B10 (aldose reductase). 92.66 0.01 FOSB FBJ murine osteosarcoma viral oncogene homolog B 92.66 0.01 FOSB FBJ murine osteosarcoma viral oncogene homolog B 97.00 0.02 ZFP36L1 zinc finger protein 36, C3H type-like 1 97.00 0.02 ZFP36L1 zinc finger protein 36, C3H type-like 1 97.00 0.02 ZFP36L1 zinc finger protein 36, C3H type-like 1 97.00 0.02 KLF2 Kruppel-like factor 2 (lung) 97.01 0.03 KLF2 Kruppel-like factor 2 (lung) 97.02 0.02 KLF5 Kruppel-like factor 5 97.03 JUND yun proto-oncogene Factors 97.04 BA21A bromodomain adjacent to zinc finger domain, 1A Factors 97.01 JUND yun proto-oncogene Factors Signal Transdu 71.70 D.02 ZFP36 zinc finger protein 36, C3H type, homolog Zinc finger protein 36, C3H type, homolog Transcriptin 71.71 D.02 ZFP36 zinc finger protein 36, C3H type, homolog Zincf inger protein 36, C3H type, homolog	9.95 0.00	ALDH4A1	aldehyde dehydrogenase 4 family, member A1	\backslash
 Solid Constant Service Servic	91.03 0.00	AKR1B10	aldo-keto reductase family 1, member B10 (aldose reductase)	
70.42 inhibitor of DNA binding 4 47.17 0.02 ZFP361.1 71.70 0.02 ZFP361.1 71.71 0.02 ZFP361.1 71.72 0.02 KLF2 Kuppel-like factor 2 (lung) 71.71 0.02 KLF3 Kruppel-like factor 4 Transcription 71.71 0.02 KLF5 Kruppel-like factor 5 Fractors 71.71 0.02 KLF5 Kruppel-like factor 4 Fractors 71.72 0.01 EGR1 9.43 0.01 JUND 9.43 0.01 JUND 9.43 0.01 JUND 9.44 bromodomain adjacent to zinc finger domain, 1A 9.45 nuclear factor 1B Factors 9.47 0.02 ZFP36 zinc finger protein 36, C3H type, homolog 12.05 0.02 ZFP36	-82.64 0.01	FOSB	FBJ murine osteosarcoma viral oncogene homolog B	
47.17 0.02 ZFP38L1 zinc finger protein 36, C3H type-like 1 14.79 0.03 KLF2 Kruppel-like factor 2 (lung) 13.62 0.02 SCA7 spinocerebellar ataxia 7 17.72 0.02 KLF4 Kruppel-like factor 4 12.59 0.00 EGR3 early growth response 3 17.17 0.02 KLF5 Kruppel-like factor 5 on cogene homolog 10.68 0.03 JUN v-jun sarcoma virus 17 oncogene homolog 10.13 0.01 EGR1 early growth response 1 10.13 0.01 EGR1 bromodog 2 10.13 0.01 EGR1 early growth response 1 10.13 0.01 EGR1 early growth response 1 10.14 0.00 NFIB nuclear factor //B 11.15 0.01 CD44 CD44 antigen 15.85 0.00 ZFP36 zinc finger protein 36, C3H type, homolog 17.51 0.00 TCF8 transcription factor 3 17.51 0.00 TCF8 transcription factor 3 17.51 0.00 CIF4 transcription factor 1 17.41 0.03 NR4A2 nuclear receptor subfamily 4, group A, member 1 17.81 0.01 PHTX1 paired-like homeodomain transcription factor 1 16.64 0.02 LEFPA leptin receptor subfamily 4, group A, member 1 17.81 0.01 PHRC1 proline-rich nuclear receptor coactivator 1 16.64 0.02 LEFPR leptin receptor subfamily 4, group A, member 1 17.81 0.01 PHRC1 proline-rich nuclear receptor coactivator 1 16.64 0.02 LEFPR leptin receptor subfamily 4, group A, member 1 17.81 0.01 AGRE1 angiotensin li receptor. 18.00 0.03 RBP1 retion binding protein 1, cellular 19.43 0.00 ADRE2 adrenergic, beta-2, receptor, surface 30.00 ADRE4	-70.42 0.01	ID4	inhibitor of DNA binding 4	
 19.37 0.02 MAPT V-mat musculaponeurous inbrosarcom oncogene nomolog P 19.36 0.02 TIEG TGFB inducible early growth response 13.62 0.02 TIEG TGFB inducible early growth response 13.62 0.02 KLF4 Kruppel-like factor 2 (lung) 12.72 0.02 KLF4 Kruppel-like factor 3 17.71 0.02 KLF5 Kruppel-like factor 5 17.71 0.02 KLF5 Kruppel-like factor 5 17.71 0.02 KLF5 Bit and the sponse 1 17.72 0.72 KLF4 Bit and the sponse 1 17.73 0.01 EGR1 early growth response 1 17.73 0.02 FFR2 period homolog 2 17.74 0.03 JUN v-jun sarcoma virus 17 oncogene homolog 17.75 0.00 FFR2 period homolog 2 17.75 0.00 NFIB nuclear factor /B 17.90 0.01 CD44 CD44 antigen 17.91 0.00 CFR4 is aplicing factor 1 17.91 0.00 CFR4 is aplicing factor 16 (finger protein 36, C3H type, homolog 17.81 0.00 CFR451 zinc finger protein 36, C3H type, homolog 17.81 0.00 CFR451 zinc finger protein 36, C3H type, homolog 17.91 0.00 CFR451 zinc finger protein 451 17.91 0.00 CFR451 zinc finger protein 451 17.91 0.01 OFCR6 transcription factor 3 17.91 0.01 OFCR6 transcription factor 4 17.91 0.01 OFCR6 transcription factor 1 17.81 0.01 CFR4 eukaryotic translation initiation factor 11 A 17.81 0.01 CFR4 interacting protein 14, group A, member 2 17.81 0.01 GFR54 adde adde adde adde adde adde adde add	-47.17 0.02	ZFP36L1	zinc finger protein 36, C3H type-like 1	
 Transcription Tarse inducible early growth response Store KLF4 Kruppel-like factor 4 Store KLF4 Kruppel-like factor 5 Comparison of the second structure of the	-19.5/ 0.02		V-mat musculoaponeurotic fibrosarcoma oncogene nomolog F	
 13.05 0.02 SCA7 spinocerebellar ataxia? 13.05 0.00 EGR3 early growth response 3 17.17 0.02 KLF5 Kruppel-like factor 5 10.68 0.03 JUN v-jun sarcoma virus 17 oncogene homolog 13.01 EGR1 early growth response 1 10.13 0.01 EGR2 period homolog 2 24.3 0.01 JUND jun D proto-oncogene 26.2 0.02 SP3 Sp3 transcription factor 27.0 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A 27.0 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A 28.7 0.00 NFIB nuclear factor <i>I/B</i> 21.00 C2 ZFP36 zinc finger protein 36, C3H type, homolog 21.01 CD44 CD44 antigen 22.02 ZFP36 zinc finger protein 451 22.01 OI CD44 activating transcription factor 3 23.7 0.01 FIF13 activating transcription factor 3 23.7 0.01 PITX1 paired-like homeodomain transcription factor 1 23.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 23.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 23.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 24.80 0.00 ADR82 adrenergic, beta-2, receptor, surface 24.90 0.01 F2RL3 transforming growth factor, beta receptor-like 1 24.30 0.00 ADR82 adrenergic, beta-2, receptor, surface 25.00 0.01 RBP1 retion binding protein 1, coagulation factor 14 angiotensin II receptor-like 1 24.30 0.00 ADR82 adrenergic, beta-2, receptor, surface 25.00 0.01 RBE1 actor of thomolog retion 1 25.00 0.02 RHEB Ras homolog enriched in brain 25.00 0.03 NFKAIA nuclear factor of Rapa light polypeptide gene enhancer alpha 25.00 0.01 PTGIS prostaglandin 12 (prostacyclin) synthase 25.30 0.02 TMEM1 transmembrane protein 1 25.40 0.02 TMEM1 transmembrane protein 1 25.50 0.03 NFKBIA hemodobin, beta 1 26.50 0.02 TMEM1 transmembrane protein 1 26.50 0.02 MFKBIA homolog forces pailight polypeptide gene enhancer alpha	-13.62 0.02	TIEG	TGFB inducible early growth response	
12.12 0.02 KLF4 Kruppel-like factor 4 12.59 0.00 EGR3 early growth response 3 11.71 0.02 KLF5 Kruppel-like factor 5 10.68 0.03 JUN vjun sarcoma virus 17 oncogene homolog Transcription 0.64 0.02 PER2 period homolog 2 Factors -9.43 0.01 JUND jun D proto-oncogene -9.43 Factors -9.43 0.01 JUND pun D proto-oncogene -9.43 Factors -9.43 0.01 JUND pun D proto-oncogene -9.43 Factors -9.43 0.01 CD44 DATA bromodomain adjacent to zinc finger domain, 1A -7.63 -7.63 Factors 12.05 0.02 ZFP36 zinc finger protein 36, C3H type, homolog -7.63 -7.61 -7.	-13.05 0.02	SCA7	spinocerebellar ataxia 7	
12.35 0:00 EGN3 early growth response 1 11.71 0.02 KLF5 Kruppel-like factor 5 10.68 0.03 JUN v-jun sarcoma virus 17 oncogene homolog Transcription -9.62 0.02 PER2 period homolog 2 Factors -9.43 0.01 JUND jun D proto-oncogene Factors -9.26 0.02 SP3 Sp3 transcription factor Factors -8.77 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A Factors -9.26 0.02 SP1 zinc finger protein 36, C3H type, homolog Transcription -8.70 0.00 NFIB nuclear factor 1/B Transcription factor 3 Transcription factor 1 12.05 0.02 ZFP36 zinc finger protein 36, C3H type, homolog Transcription 12.05 0.00 ZFP36 zinc finger protein 451 Transcription factor 8 Transcription factor 1 12.05 0.00 ZFP36 zinc finger protein 451 Activating transcription factor 1 Receptors 6.27 0.01 PITX paired-like homeodomain transcription factor 1	-12.72 0.02	KLF4	Kruppel-like factor 4	
10:68 0:03 JUN -yijn*sarcoma virus 17 oncogene homolog Transcription 10:13 0.01 EGR1 early growth response 1 Factors -9.62 0.02 PER2 period homolog 2 Factors -9.43 0.01 JUND jun D proto-oncogene Factors -9.26 0.02 SP3 Sp3 transcription factor Factors -8.77 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A Factors -8.77 0.04 SF1 spicing factor 1 Bazine factor I/B Signal Transcription factor 3 12.65 0.02 ZFP36 zinc finger protein 36. C3H type, homolog Transcription 17.51 0.04 ATF3 activating transcription factor 3 Transcription factor 1 -6.27 0.01 PIFX1 paired-like homeodomain transcription factor 1A Transcription -7.83 0.00 TGFBR3 transforming growth factor, surface Receptors -7.83 0.01 PNRC1 proline-rich nuclear receptor subfamily 4, group A, member 1 Receptors -7.84 0.01 FGBR3 transforming growth factor, su	-11.71 0.02	KLF5	Kruppel-like factor 5	
10.13 0.01 EGR1 early growth response 1 -9.43 0.02 PER2 period homolog 2 -9.43 0.01 JUND jun D proto-oncogene -9.26 0.02 SP3 Sp3 transcription factor -9.27 0.04 BA21A bromodomain adjacent to zinc finger domain, 1A -8.77 0.04 BA21A bromodomain adjacent to zinc finger domain, 1A -8.77 0.04 BA21A bromodomain adjacent to zinc finger domain, 1A -8.77 0.04 CD44 antigen 15.85 0.03 SF1 splicing factor 1 15.85 0.00 ZNF451 zinc finger protein 36, C3H type, homolog -8.85 0.00 ZNF451 zinc finger protein 451 42.19 0.04 ATF3 activating transcription factor 3 -9.43 0.03 OSR2 odd-skipped-related 2A protein 10.06 0.02 EIF1A eukaryotic translation initiation factor 1A -9.43 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 1 -7.81 0.01 TGFBR3 transcring protein 18.60 0.03 RBP1 receptor -8.93 0.00 TGFBR3 transcring protein 18.60 0.03 RBP1 retion binding protein 1, cellular -8.06 0.02 ERBE32IP erbb2 interacting protein -8.06 0.02 RHEB Ras homolog eriched in brain -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface -9.43 0.00 ADRB2 prostagiandin 12 (prostacyclin) synthase -9.43 0.00 PTGIS prostagiandin 12 (prostacyclin) synthase -9.58 0.04 NCKAP1 NCK-associated protein 1 -9.58 0.04 HBB hemodolon. Deta	-10.68 0.03	JUN	v-jun sarcoma virus 17 oncogene homolog	
 -3.43 0.012 FER2 period nonloteg 2 -3.43 0.01 JUND jun D proto-oncogene -3.62 0.02 SP3 Sp3 transcription factor -3.77 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A -8.77 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A -8.77 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A -8.77 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A -8.77 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A -8.77 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A -8.76 0.00 ZHF451 zinc finger protein 451 -8.85 0.00 ZHF451 zinc finger protein 451 -8.85 0.00 TCF8 transcription factor 3 -7.51 0.00 TCF8 transcription factor 3 -7.51 0.00 TCF8 transcription factor 4 -9.43 0.01 PITX1 paired-like homeodomain transcription factor 1 -9.43 0.03 OSR2 odd-skipped-related 2A protein -8.39 0.00 TGFBR3 transforming growth factor, beta receptor 1II -8.40 0.02 ERBB2IP erbb2 interacting protein 1, cellular -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface -9.43 0.02 RHEB Ras homolog orriched in brain -9.43 0.03 NFKAI1 angiotensin II receptor-like 1 -9.43 0.04 NCKAP1 NCK-associated protein 1 -9.43 0.02 FIGIS prostaglandin 12 (prostacyclin) synthase -9.44 HBB Ras homolog ariched in brain -7.69 0.04 NCKAP1 NCK-associated protein 1 -9.50 0.03 NFKBIA nuclear factor of kapa light polypeptide gene enhancer alpha Signaling cascades -9.44 HBB hemoglobin, beta 	-10.13 0.01	EGR1	early growth response 1	
 9.26 0.02 SP3 Sp3 transcription factor 8.77 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A 8.70 0.00 NFIB nuclear factor 1/B 9.16 pintor finger protein adjacent to zinc finger domain, 1A 9.17 pintor finger protein adjacent to zinc finger domain, 1A 9.18 pintor finger protein adjacent to zinc finger domain, 1A 9.18 pintor finger protein adjacent to zinc finger domain, 1A 9.27 0.01 CD44 CD44 antigen 9.28 0.00 ZNF451 zinc finger protein 451 9.21 0.00 TCF8 transcription factor 3 9.23 0.00 TCF8 transcription factor 8 0.27 0.01 PITX1 paired-like homeodomain transcription factor 1A 9.43 0.03 OSR2 odd-skipped-related 2A protein 9.43 0.03 OSR2 odd-skipped-related 2A protein 9.43 0.03 OSR2 odd-skipped-related 2A protein 9.43 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 9.78 0.00 TGFBR3 transforming growth factor, beta receptor 1II 8.80 0.02 ERBE2IP erbb2 interacting protein 8.80 0.03 RBP1 retinol binding protein 1, cellular retinol binding protein 1, cellular 9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface 8.80 0.02 RHEB Ras homolog enriched in brain 9.43 0.02 FZD7 frizzled homolog 7 (Drosophila) 9.758 0.04 NCKAP1 NCK-associated protein 1 8.84 0.00 PTGDS prostaglandin 12 (prostacyclin) synthase 8.84 0.00 PTGDS prostaglandin 20 synthase 8.83 0.00 TGFBB hemodobin beta 	-9.62 0.02		un D proto-oncogene	
-8.77 0.04 BAZ1A bromodomain adjacent to zinc finger domain, 1A -8.70 0.00 NFIB nuclear factor I/B +1.15 0.01 CD44 CD44 antigen 15.85 0.03 SF1 splicing factor 1 15.85 0.00 ZNF451 zinc finger protein 451 42.19 0.04 ATF3 activating transcription factor 3 17.51 0.00 TCF8 transcription factor 4 6.27 0.01 PITX1 paired-like homeodomain transcription factor 1 -9.43 0.03 OSR2 odd-skipped-related 2A protein 10.06 0.02 EIF1A eukaryotic translation initiation factor 1A 57.14 0.03 NR4A2 nuclear receptor subfamily 4, group A, member 2 38.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 -7.81 0.01 PNRC1 proline-rich nuclear receptor coactivator 1 -7.83 0.00 TGFBR3 transforming growth factor, beta receptor III 16.64 0.02 EBR31 reation protein 1, cellular 8.80 0.03 RBP1 etholoind factor 11 (thrombin) receptor-like 1 -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface 6.33 0.01 AGTRL1 angiotensin I receptor-like 1 -9.43 0.02 RHEB Ras homolog enriched in brain -9.33 0.02 FZD7 frizzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha 5.50 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.13 0.02 TMEM1 transmembrane protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.13 0.02 TMEM1 transmembrane protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.13 0.02 TMEM1 transmembrane protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.13 0.02 TMEM1 transmembrane protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.13 0.02 TMEM1 transmembrane protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.13 0.02 TMEM1 transmembrane protein 1 -8.55 0.03 NFKBIA huclear factor of kappa light polypeptide gene enhancer alpha -8.51 0.04 HBB hemolobin. beta	-9.26 0.02	SP3	Sp3 transcription factor	
 -8.70 0.00 NFIB nuclear factor I/B -8.71 0.00 NFIB rulear factor I/B 11.15 0.01 CD44 CD44 antigen 15.85 0.03 SF1 splicing factor 1 12.05 0.02 ZFP36 zinc finger protein 36, C3H type, homolog -8.85 0.00 ZNF451 zinc finger protein 451 42.19 0.04 ATF3 activating transcription factor 3 17.51 0.00 TCF8 transcription factor 3 6.27 0.01 PITX1 paired-like homeodomain transcription factor 1 -9.43 0.03 OSR2 odd-skipped-related 2A protein 10.06 0.02 EIF1A eukaryotic translation initiation factor 1A 57.14 0.03 NR4A2 nuclear receptor subfamily 4, group A, member 2 38.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 38.76 0.02 LEPR leptin receptor -8.80 0.02 EBB2IP erbb2 interacting protein 8.80 0.03 RBP1 retion factor 11 (thrombin) receptor-like 1 -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface -8.30 0.01 AGTRL1 angiotensin II receptor-like 1 -9.43 0.02 RHEB Ras homolog enriched in brain -9.33 0.02 FZD7 frizzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.51 0.03 PKBIA -8.52 0.03 NFKBIA -8.54 0.00 PTGDS prostaglandin 12 (prostacyclin) synthase -8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous 	-8.77 0.04	BAZ1A	bromodomain adjacent to zinc finger domain, 1A	
 A.1.1 0.01 GD44 Signal Transfer A.1.1 0.01 CF8 transcription factor 1 A.1.1 0.01 CF8 transcription factor 3 A.1.1 0.01 PTX1 paired-like homeodomain transcription factor 1 A.2.3 0.03 OSR2 odd-skipped-related 2A protein A.2.3 0.03 OSR2 nuclear receptor subfamily 4, group A, member 2 A.2.4 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 A.2.5 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 1 A.3.9 0.00 TGFBR3 transforming growth factor, beta receptor III A.6.4 0.02 LEFR leptin receptor B.80 0.03 RBP1 retinol binding protein 1, cellular A.3.0 0.04 AGTRL1 angiotensin II receptor-like 1 A.3.0 0.02 RHEB Ras homolog enriched in brain A.3.3 0.02 FZD7 frizzled homolog 7 (Drosophila) A.7.69 0.04 NCKAP1 NCK-associated protein 1 A.8.5 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha A.3.1 0.02 TMEM1 transmembrane protein 1 Miscellaneous 	-8.70 0.00	NFIB CD44	nuclear factor I/B	
12.05 0.02 ZFP36 zinc finger protein 36, C3H type, homolog Signal Transdi -8.85 0.00 ZNF451 zinc finger protein 451 scivating transcription factor 3 Transcription factor 3 17.51 0.00 TCF8 transcription factor 8 Transcription factor 1 Transcription factor 1 -9.43 0.03 OSR2 odd-skipped-related 2A protein Transcription factor 1 10.06 0.02 EIF1A eukaryotic translation initiation factor 1A Transforming growth factor, beta receptor subfamily 4, group A, member 2 38.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 1 Receptors -8.93 0.00 TGFBat transforming growth factor, beta receptor lill Receptors 16.64 0.02 LEPR leptin receptor erbiz interacting protein 1, cellular coagulation factor II (thrombin) receptor-like 1 G- protein 8.80 0.03 RBFL1 angiotensin 1 rezeptor, surface G- protein -8.33 0.04 ACRL1 angiotensin 1 receptor) G- protein -8.33 0.02 REB2IP retino binding protein 1, cellular G- protein	-15.85 0.03	SF1	splicing factor 1	
-8.85 0.00 ZNF451 zinc finger protein 451 42.19 0.04 ATF3 activating transcription factor 3 Transcription factor 7 6.27 0.01 PITX1 paired-like homeodomain transcription factor 1 -9.43 0.03 OSR2 odd-skipped-related 2A protein 10.06 0.02 EIF1A eukaryotic translation initiation factor 1A 57.14 0.03 NR4A2 nuclear receptor subfamily 4, group A, member 2 38.76 0.03 NR4A2 nuclear receptor subfamily 4, group A, member 1 -7.81 0.01 PNRC1 proline-rich nuclear receptor coactivator 1 -8.93 0.00 TGFBR3 transforming growth factor, beta receptor III 10.64 0.02 EIFPR leptin receptor -8.06 0.02 ERBB2IP erbb2 interacting protein 10.47 0.01 F2RL1 coagulation factor II (thrombin) receptor-like 1 -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface -8.30 0.01 AGTRL1 angiotensin II receptor/like 1 -9.43 0.00 NREB1 angiotensin 1 receptor/like 1 -9.43 0.00 NREB2 adrenergic, beta-2-, receptor, surface -8.30 0.02 RHEB Ras homolog enriched in brain -9.35 0.02 RHEB Ras homolog enriched in brain -9.35 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.76 0.00 PTGDS prostaglandin 12 (prostacyclin) synthase -8.13 0.02 TMEM1 transmembrane protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.13 0.02 TMEM1 transmembrane protein 1 -8.55 0.04 HBB hemolobin D2 synthase	-12.05 0.02	ZFP36	zinc finger protein 36, C3H type, homolog	Signal Transduct
42.19 0.04 A1F3 activating transcription factor 3 17.51 0.00 TCF8 transcription factor 3 9.43 0.03 OSR2 odd-skipped-related 2A protein 10.06 0.02 EIF1A eukaryotic translation initiation factor 1A 57.14 0.03 NR4A2 nuclear receptor subfamily 4, group A, member 2 38.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 38.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 1 -7.81 0.01 PNRC1 proline-rich nuclear receptor coactivator 1 -8.39 0.00 TGFBR3 transforming growth factor, beta receptor III -8.64 0.02 ERBB2IP erbb2 interacting protein -8.80 0.03 RBP1 retion binding protein 1, cellular -8.33 0.00 AGRE1 angiotensin factor 10 (Ithrombin) receptor-like 1 -8.43 0.00 AGRE2 adrenergic, beta-2-, receptor, surface G- protein -8.30 0.02 RHEB Ras homolog enriched in brain fractor of kappa light polypeptide gene enhancer alpha -8.55 0.03	-8.85 0.00	ZNF451	zinc finger protein 451	Transcription
17.30 0.00 1010 tansenigenerative factor 0 17.31 0.01 PITX1 paired-like homeodomain transcription factor 1 -9.43 0.03 OSR2 odd-skipped-related 2A protein 10.06 0.02 EIF1A eukaryotic translation initiation factor 1A 57.14 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 38.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 1 -7.81 0.01 PNRC1 proline-rich nuclear receptor coactivator 1 -8.93 0.00 TGFBR3 transforming growth factor, beta receptor III Receptors 16.64 0.02 ERBB2IP leptin receptor Receptors -8.06 0.02 ERBB2IP retiol binding protein 1, cellular receptor-like 1 -9.43 0.00 AGTRL1 caoguation factor II (thrombin) receptor-like 1 G- protein -8.06 0.02 RHEB Ras homolog enriched in brain frzzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCKAP1 (Aspa light polypeptide gene enhancer alpha Signaling -8.55 0.03 NFKBIA nuclear	-42.19 0.04	AIF3	activating transcription factor 3	
-9.43 0.03 OSR2 idd-skipped-related 2A protein 10.06 0.02 EIF1A eukaryotic translation initiation factor 1A 57.14 0.03 NR4A2 nuclear receptor subfamily 4, group A, member 2 38.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 2 7.81 0.01 PNRC1 proline-rich nuclear receptor coactivator 1 -8.93 0.00 TGFBR3 transforming growth factor, beta receptor 1II 16.64 0.02 ERBB2IP erbb2 interacting protein 8.80 0.02 ERBB2IP erbb2 interacting protein 1, cellular -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface 6.83 0.01 AGTRL1 angiotensin II receptor-like 1 -9.43 0.02 RHEB Ras homolog enriched in brain -9.35 0.02 FZD7 frizzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.54 0.00 PTGDS prostagiandin 12 (prostacyclin) synthase -8.13 0.02 TMEM1 transmembrane protein 1 -8.54 0.00 PTGDS prostagiandin 12 synthase -8.13 0.02 TMEM1 transmembrane protein 1 -8.55 0.03 NFKBIA huclear factor of kappa light polypeptide gene enhancer alpha	6.27 0.01	PITX1	paired-like homeodomain transcription factor 1	1
10.06 0.02 EIF1A eukaryotic translation initiation factor 1A 57.14 0.03 NR4A2 nuclear receptor subfamily 4, group A, member 2 38.76 0.03 NR4A1 nuclear receptor subfamily 4, group A, member 1 -7.81 0.01 PNRC1 proline-rich nuclear receptor coactivator 1 -8.93 0.00 TGFBR3 transforming growth factor, beta receptor lll 16.64 0.02 LEPR leptin receptor -8.06 0.02 ERBB2IP erbto binding protein 1, cellular 6.80 0.03 RBP1 retinoi binding protein 1, cellular -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface -8.04 0.02 RHEB Ras homolog enriched in brain -9.43 0.04 NCKAP1 NCK-associated protein 1 -8.05 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -9.35 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha -8.54 0.00 PTGDS prostaglandin 12 (prostacyclin) synthase	-9.43 0.03	OSR2	odd-skipped-related 2A protein	
57.14 0.03 NR4A2 Indicear receptor subfamily 4, group A, member 1 -7.81 0.01 PNRC1 proline-rich nuclear receptor soubfamily 4, group A, member 1 -7.81 0.01 PSRC1 proline-rich nuclear receptor coactivator 1 -8.93 0.00 TGFBR3 transforming growth factor, beta receptor III -8.04 0.02 LEPR leptin receptor -8.05 0.03 RBP1 retinol binding protein 1, cellular -8.05 0.03 RBP1 retinol binding protein 1, cellular 10.47 0.01 F2RL1 coagulation factor II (thrombin) receptor-like 1 -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface -8.05 0.02 RHEB Ras homolog enriched in brain -9.43 0.02 FZD7 frizzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha 15.70 0.01 PTGIS prostaglandin 12 (prostacyclin) synthase -8.13 0.02 TMEM1 trasmembrane protein 1 <t< td=""><td>-10.06 0.02</td><td>EIF1A</td><td>eukaryotic translation initiation factor 1A</td><td></td></t<>	-10.06 0.02	EIF1A	eukaryotic translation initiation factor 1A	
0.03 NRMA1 Indicating transforming growth factor, beta receptor cacitivator 1 -8.33 0.00 TGFBR3 transforming growth factor, beta receptor cacitivator 1 -8.33 0.00 TGFBR3 transforming growth factor, beta receptor cacitivator 1 -8.64 0.02 LEPR leptin receptor -8.06 0.02 ERBS2IP erbb2 interacting protein -8.06 0.01 F2RL1 coagulation factor II (thrombin) receptor-like 1 -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface G- protein -8.30 0.02 RHEB Ras homolog enriched in brain Frizzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCKAP1 NCKAP1 Signaling -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha Signaling 15.70 0.01 PTGIS prostaglandin D2 synthase cascades -8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous	-57.14 0.03	NR4A2 NR4A1	nuclear receptor subfamily 4, group A, member 2	
-8.93 0.00 TGFBR3 transforming growth factor, beta receptor III 16.64 0.02 LEPR leptin receptor 8.80 0.02 ERBB2IP erbb2 interacting protein 8.80 0.03 RBP1 retinol binding protein 1, cellular 10.47 0.01 F2RL1 coagulation factor II (thrombin) receptor-like 1 -9.43 0.00 ADR2 adrenergic, beta-2-, receptor, surface 6.83 0.01 AGTRL1 angiotensin II receptor-like 1 -9.35 0.02 RHEB Ras homolog enriched in brain -9.35 0.02 FZD7 frizzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha 15.70 0.01 PTGIS prostaglandin I2 (prostacyclin) synthase -8.13 0.02 TMEM1 transmembrane protein 1 -8.54 0.00 HBB hemolobin, beta	-7.81 0.01	PNRC1	proline-rich nuclear receptor coactivator 1	
16.64 0.02 LEPR leptin receptor 8.06 0.02 ERBB2IP erbb2 interacting protein 8.80 0.03 RBP1 retinol binding protein 1, cellular 10.47 0.01 FZRL1 coagulation factor II (thrombin) receptor-like 1 9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface G- protein 6.83 0.01 AGTRL1 angiotensin II receptor-like 1 G- protein -8.04 0.02 FZD7 frizzled homolog enriched in brain G- protein -9.35 0.02 FZD7 frizzled homolog 7 (Drosophila) G- protein -7.69 0.04 NCKAP1 NCK-associated protein 1 Signaling -7.69 0.04 NCKAP1 NCK-associated protein 1 cascades 15.70 0.01 PTGIS prostaglandin 12 (prostacyclin) synthase cascades 18.94 0.00 PTGDS prostaglandin D2 synthase cascades -8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous	-8.93 0.00	TGFBR3	transforming growth factor, beta receptor III	
4.000 RBP1 retinol binding protein 1, cellular 10.47 0.01 F2RL1 coagulation factor II (thrombin) receptor-like 1 -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface G- protein 6.83 0.01 AGTRL1 angiotensin II receptor-like 1 G- protein -8.05 0.02 RHEB Ras homolog enriched in brain G- protein -9.35 0.02 FZD7 frizzled homolog 7 (Drosophila) FZD7 -7.69 0.04 NCKAP1 NCK-associated protein 1 Signaling -8.75 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha Signaling 15.70 0.01 PTGIS prostaglandin I2 (prostacyclin) synthase cascades -8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous	-16.64 0.02		leptin receptor	
10.47 0.01 F2RL1 coagulation factor II (thrombin) receptor-like 1 -9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface G- protein -8.33 0.01 AGTRL1 angiotensin II receptor-like 1 G- protein -8.06 0.02 RHEB Ras homolog enriched in brain Fizzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCK-associated protein 1 Signaling -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha Signaling 15.70 0.00 PTGIS prostaglandin I2 (prostacyclin) synthase Signaling -8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous	8.80 0.02	RBP1	retinol binding protein 1, cellular	
-9.43 0.00 ADRB2 adrenergic, beta-2-, receptor, surface G- protein 6.83 0.01 AGTRL1 angiotensin II receptor-like 1 -9.06 0.02 RHEB Ras homolog enriched in brain -9.35 0.02 FZD7 frizzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha Signaling 15.70 0.00 PTGIS prostaglandin 12 (prostacyclin) synthase cascades -8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous	-10.47 0.01	F2RL1	coagulation factor II (thrombin) receptor-like 1	
6.83 0.01 AGTRL1 angiotensin II receptor-like 1 -8.06 0.02 RHEB Ras homolog enriched in brain -8.05 0.02 FZD7 frizzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha Signaling 15.70 0.01 PTGIS prostaglandin 12 (prostacyclin) synthase cascades 18.94 0.00 PTGDS prostaglandin D2 synthase cascades -8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous	-9.43 0.00	ADRB2	adrenergic, beta-2-, receptor, surface - G- protein	
-0.35 0.02 FZD7 frizzled homolog 7 (Drosophila) -7.69 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha 15.70 0.01 PTGIS prostaglandin I2 (prostacyclin) synthase -8.13 0.02 TMEM1 transmembrane protein 1 -8.55 0.04 HBB hemolobin, beta	6.83 0.01	AGTRL1	angiotensin II receptor-like 1	
-7.69 0.04 NCKAP1 NCK-associated protein 1 -8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha 15.70 0.01 PTGIS prostaglandin I2 (prostacyclin) synthase -8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous	-9.35 0.02	FZD7	frizzled homolog 7 (Drosophila)	
-8.55 0.03 NFKBIA nuclear factor of kappa light polypeptide gene enhancer alpha Signaling 15.70 0.01 PTGIS prostaglandin l2 (prostacyclin) synthase -8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous	-7.69 0.04	NCKAP1	NCK-associated protein 1	
15.7U U.U1 PIGIS prostaglandin I2 (prostacyclin) synthase cascades 18.94 0.00 PTGDS prostaglandin D2 synthase -8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous cascades	-8.55 0.03	NFKBIA	nuclear factor of kappa light polypeptide gene enhancer alpha	
-8.13 0.02 TMEM1 transmembrane protein 1 Miscellaneous	-15.70 0.01	PTGIS	prostaglandin 12 (prostacyclin) synthase cascades	
9.58 0.04 HBB hemoglobin, beta J Miscellaneous	-8.13 0.02	TMEM1	transmembrane protein 1	
	9.58 0.04	HBB	hemoglobin, beta Miscellaneous	

Fig. 4 A hundred top regulated genes. Fold changes are shown in left columns. *P*-values, gene symbols and unigene comments are given next. The genes are marked with brackets and grouped according to cellular functions and biological processes.

В	
FC P-value SYMBOL	Unigene Comment
-11.24 0.00 HAS1 6.49 0.02 EVA1	hyaluronan synthase 1 epithelial V-like antigen 1 Adhesion molecules,
17.19 0.01 DSC2	desmocollin 2
-11.30 0.03 PDZK3	PDZ domain containing 3
-8.06 0.03 RABGGTB -9.71 0.00 DMN	Rab geranylgeranyltransferase, beta subunit Contact and Motility
-10.00 0.01 ADD3 23.94 0.00 KRT6A	adducin 3 (gamma)
37.66 0.01 KRT6B	keratin 6B
6.47 0.00 GMFG	glia maturation factor, gamma
-29.94 0.04 TNA -21.32 0.02 TNXB	tenascin XB
-11.20 0.01 MAGP2 6.88 0.00 COL5A3	collagen, type V, alpha 3
7.53 0.05 COL4A2 8.48 0.00 COL5A1	collagen, type IV, alpha 2 ECM collagen, type V, alpha 1
19.25 0.02 COL4A1 38.57 0.01 COL11A1	collagen, type IV, alpha 1
-9.17 0.03 APP	amyloid beta (A4) precursor protein
7.95 0.05 WFDC1 18.41 0.02 KLK13	kallikrein 13
25.63 0.02 MMP11 30.60 0.01 KLK6	matrix metalloproteinase 11 (stromelysin 3) Proteolysis
32.06 0.01 HAT 7.95 0.00 UBE2C	airway trypsin-like protease ubiguitin-conjugating enzyme E2C
6.51 0.03 CSTB 22.06 0.03 SERPINB13	cystatin B (stefin B)
94.96 0.00 SERPINB4	serine (or cysteine) proteinase inhibitor, member 4
143.80 0.00 SERPINBS 146.50 0.00 PI3	protease inhibitor 3, skin-derived (SKALP)
12.84 0.01 THY1 6.36 0.00 TRB	Thy-1 cell surface antigen
9.40 0.00 TRA -48.78 0.00 DAF	T cell receptor alpha locus decay accelerating factor for complement
-8.77 0.00 CD83	CD83 antigen
13.67 0.02 IGKV10R2-108	immunoğlobulin kappa variable 1/OR2-108
37.27 0.01 IGKV1D-13	immunoglobulin kappa variable 1D-13 immunoglobulin kappa constant
67.16 0.01 MGC27165	hypothetical protein MGC27165
96.56 0.00 IGL	immunoglobulin lambda locus
126.70 0.00 IGHG3 -12.06 0.04 IL6	immunoglobulin heavy constant gamma 3
63.08 0.05 DEFB4	defensin, beta 4 Secreted
22.78 0.00 S100A12	S100 calcium binding protein A12 (calgranulin C) S100 family
-9.71 0.00 KAD21 -7.87 0.01 STAG2	stromal antigen 2 DNA repair.
7.48 0.02 UPP1 8.79 0.01 CDA	uridine phosphorylase 1 Synthesis
13.66 0.00 CHN1	chimerin (chimaerin) 1
-10.80 0.01 WEE1	WEE1 homolog
-8.77 0.01 INSIG1	Insulin induced gene 1
10.33 0.01 EGFL6	EGF-like-domain, multiple 6
7.07 0.02 NDRG4	NDRG family member 4
-30.96 0.05 APOD	apolipoprotein D
-14.31 0.04 CXCL2	chemokine (C-X-C motif) ligand 2
-22.83 0.00 THH	trichohyalin
-8.70 0.03 FLG 8.10 0.00 IVL	filaggrin involucrin
15.72 0.00 SPRR1B 130.70 0.01 SPRR3	small proline-rich protein 1B (cornifin)
33.35 0.00 SPRR1A 118.00 0.00 S100A9	small proline-rich protein 1A S100 calcium binding protein A9 (calgranulin B))
105.80 0.01 S100A7 10.96 0.02 CALML3	S100 calcium binding protein A7 (psoriasin 1) S100 family

Fig. 4 Continued.



Fig. 5 K17 is up-regulated in non-healing edges of venous ulcers. (**A**) Real-time PCR confirms K17 up-regulation in ulcers. K17 expression was normalized to expression level of HPRT. (**B**) Immunofluorescence with K17-specific antibody shows induction of K17 in non-healing edge of venous ulcer. Scale bar 50 μm.

cyclin-dependent kinase inhibitor 2B (CDKN2B) and cyclindependent kinase inhibitor 3 (CDKN3) were up-regulated. Deregulation of cell cycle associated genes suggest a loss of cell cycle control, which may account for the hyperproliferative potential of the keratinocytes present in the epidermis of venous ulcers.

Keratinocyte activation: regulators

Among secreted molecules that participate in keratinocyte activation, insulin-like growth factor binding protein 5 (IGFBP5) was among top 50 down-regulated genes. Furthermore, bone morphogenetic proteins (BMP) were differentially regulated. The expression of BMP-2 and BMP-7 was down-regulated (Fig. 6A), whereas the expression of BMP1 was up-regulated. Furthermore, we found that the leptin receptor was down-regulated; however, there was no change in leptin expression. Angiogenesis factors, vascular endothelial growth factor (VEGF), epiregulin (EREG) and angiopoetin-like 6 (ANGPTL6) were markedly down-regulated. Previous data have shown that ANGPTL6 promotes epidermal proliferation, remodelling and regeneration [26]. Conversely, we detected induction of additional pro-angiogenic growth factors and receptors, such as platelet-derived endothelial cell growth factor (ECGF1), receptor neuropilin (NRP1) and stromal cell-derived factor $1-\alpha$ (CXCL12/SDF-1 α). We have found profound down-regulation of apolipoprotein D (APOD) and up-regulation of defensin B4 (DEFB4) (Fig. 6B). Up-regulation of DEFB4 has been shown to be associated with benign hyperplasia in skin [27].

Chemokines which mediate T cell chemotaxis were found suppressed. The expression of cutaneous T-cell attracting chemokine (CCL27), was almost abolished (Fig. 6C), along with IL-7, which is essential for T-cell memory generation, while the expression of IL7R was induced. Surprisingly, the expression of platelet-derived growth factors α and β (PDGFA and PDGFB) was increased, but the expression of transforming growth factor- β_2 (TGF β_2), transforming growth factor β receptor III (TGF- β R3), fibroblast growth factor 13 (FGF13) and interleukin 6 (IL-6) was decreased. Expression of the stromelysin-3 gene (MMP-11) was up-regulated (Fig. 6C), consistent with previously published data [28].

In summary, microarray data show changes consistent with morphology, suggesting deregulation and incomplete activation of keratinocytes at the non-healing edge in epidermis of venous ulcers.

Keratinocyte differentiation: markers, cornified envelope and barrier formation

In intact skin, the major role of keratinocyte terminal differentiation is to form a physical barrier that acts as permeability barrier against water loss, foreign microbes and toxins. The cornified cell envelope and TJs [7] are two important components of skin barrier function.

Microarray data obtained from this study confirm epidermal morphology of non-healing edges. Early markers of differentiating keratinocytes, K1 and K10, were down-regulated as well as the late markers, filaggrin (FLG) and thrichohyalin (THH), which are molecules that associate with the keratin cytoskeleton during terminal differentiation (Fig. 7). Interestingly, additional components of the cornified envelope, including involucrin (IVL) and small proline-rich proteins (SPRR1A, SPRR1B, SPRR2B, SPRR3) were up-regulated, whereas transglutaminase 1 (TGM1), an enzyme responsible for cross-linking SPRR's and IVL into the cornified envelope, was up-regulated. To confirm microarray data at the protein level, we used immunohistochemistry and stained patients' biopsy specimens with K10, IVL and FLG-specific antibodies. We found robust increase of IVL, whereas K10 and FLG were barely detected in specimens derived from venous ulcers



Fig. 6 Real-time PCR confirmation of selected genes differentially expressed in healthy skin and venous ulcers. Quantitative real-time PCR for the expression of BMP2 and BMP7 (A), APOD and DEFB4 (B), CCL27 and MMP11 (C), S100A7 and KLK6 (D). Mean values of expression levels were represented after normalization to expression level of HPRT1.



(Fig. 8). Among newly identified potential markers of keratinocyte terminal differentiation [29], we found skin-derived protease inhibitor 3 (SKALP/PI3), oxysterol-binding protein-like 8 (OSBPL8), adducing 3 (ADD3), early growth response 3 (EGR3), inhibitor of DNA binding 4 (ID4), occluding (OCLN) and decay-accelerating factor for complement (DAF) down-regulated, whereas septin 8 (SEPT8), serine/threonine kinase 10 (STK10) and serine/cysteine proteinase inhibitor, clade B, member 3 (SER-PINB3) were up-regulated (Fig. 7). In addition, several other molecules that participate in epidermal differentiation were found to be regulated. S100A7, a member of human epidermal differentiation (KLK6) were among the top up-regulated genes. We used real-

time PCR to confirm these findings (Fig. 6D). TJ in skin are complex structures localized in granular layer. These junctions are composed of transmembrane (claudin 1–20, ocludin) and plaque (symplekin (SYMPK) and ZO 1–3) proteins [30, 31]. We found that different structural components of TJs, such as TJ protein 3 (ZO3, TJP3), spectrin 1(SPTBN1), InaD-like protein (MUPP1, INADL), occludin (OCLN), claudin 5 (CLDN5), claudin 8 (CLDN8) down-regulated in the non-healing edge of venous ulcers. Interestingly, only SYMPK was found up-regulated. Formation of TJs in epidermis, during differentiation, is a precisely regulated spatiotemporal process. An important component of this regulation is polarity complex Par3, Par6, atypical PKC-iota (PARD) and CDC42 [32]. We found that different components of polarity

old Change	P-value	Biological Function	SYMBOL	Unigene Comment
17.19	0.01	Adhesion	DSC2	desmocollin 2
-2.71	0.02	Adhesion	DSC3	desmocollin 3 desmoglain 3
-3.24	0.01	Adhesion	TJP3	tight junction protein 3 (zona occludens 3)
-3.19	0.01	Adhesion	INADL	InaD-like protein
-2.05	0.02	Adhesion	OCLN	occludin
-2.87	0.02	Adhesion	CLDN5	claudin 5
-6.17	0.00	Adhesion	CLDN8	claudin 8
2.12	0.01	Adhesion	SYMPK DSC2	symplekin deemenloin 2
-3.57	0.04	Adhesion	DSB	desmonlakin
-2.10	0.00	Adhesion	PKP2	plakophilin 2
3.43	0.01	Cell cycle	SEPT	septin 8
-2.31	0.05	Cell cycle	PARD3	par-3 partitioning defective 3 homolog
2.76	0.00	Cell cycle	CCNA2	cyclin A2
4.82	0.00	Cell cycle	CCND2	cyclin B1 cyclin D2
2.87	0.02	Cell cycle	CONF	cyclin E
3.45	0.02	Cell cycle	CNNM4	cyclin M4
-3.70	0.03	Cell cycle	CCND1	cyclin D1 (PRAD1)
-3.86	0.02	Cell cycle	CHES1	checkpoint suppressor 1
-10.80	0.01	Cell cycle	WEE1	WEE1 homolog)
3.49	0.02	Cell cycle	CDKN3 CDKN2R	cyclin-dependent kinase inhibitor 3 guelin dependent kinase inhibitor 3P (p15, inhibito CDK4)
-22.83	0.00	Cytoskeletal	THH	trichohvalin
-4.88	0.00	Cytoskeletal	SPTBN1	spectrin, beta, non-erythrocytic 1
-3.69	0.02	Cytoskeletal	KRT1	keratin 1
-4.90	0.01	Cytoskeletal	KRT10	keratin 10
40.20	0.04	Cytoskeletal	KRT16	keratin 16
-10.00	0.01	Cytoskeletal	ADD3	adducin 3
-2.97	0.05	Cvtoskeletal	CDC42	cell division cycle 42
-8.70	0.03	Epidermal differentiation	FLG	filaggrin
8.10	0.00	Epidermal differentiation	IVL	involucrin
33.35	0.00	Epidermal differentiation	SPRR1A	small proline-rich protein 1A
15.72	0.00	Epidermal differentiation	SPRR1B	small proline-rich protein 1B (cornifin)
130.70	0.01	Epidermal differentiation	SPRR2B SPRR3	small proline-rich protein 28
5.37	0.01	Epidermal differentiation	TGM1	transolutaminase 1
105.80	0.01	Epidermal differentiation	S100A7	S100 calcium binding protein A7 (psoriasin 1)
95.11	0.02	Epidermal differentiation	S100A8	S100 calcium binding protein A8 (calgranulin A)
118.00	0.00	Epidermal differentiation	S100A9	S100 calcium binding protein A9 (calgranulin B)
22.78	0.00	Epidermal differentiation	S100A12	S100 calcium binding protein A12 (calgranulin C)
-5.41	0.00	Metabolism	OSBPI 8	oxysterol hinding protein-like 8
2.23	0.02	Protein kinase	STK10	serine/threonine kinase 10
146.50	0.00	Proteolysis inhibitor	PI3	protease inhibitor 3, skin-derived (SKALP)
143.80	0.00	Proteolysis inhibitor	SERPINB3	serine (or cysteine) proteinase inhibitor, member 3
30.60	0.01	Proteolysis	KLK6	kallikrein 6 (neurosin, zyme)
25.63	0.02	Recentor cyto, chemokine	IL 7R	interleukin 7 recentor
2.74	0.03	Receptor, growt factor	NRP1	neuropilin 1
-8.93	0.00	Receptor, growt factor	TGFBR3	transforming growth factor, beta receptor III
-2.10	0.01	Regulator	PLD1	phospholipase D1, phophatidylcholine-specific
2.82	0.02	Regulator	PLD2	phospholipase D2
2.49	0.04	Regulator, Notch pathway Regulator, Notch pathway	MENG NOTCH2	Match homolog
-2.11	0.00	Regulator, Rb pathway	RBL1	retinoblastoma-like 1 (p107)
-5.18	0.02	Regulator, Rb pathway	RBL2	retinoblastoma-like 2 (p130)
-124.38	0.00	Secreted	IGFBP5	insulin-like growth factor binding protein 5
6.39	0.00	Secreted	BMP1	bone morphogenetic protein 1
-3.95	0.01	Secreted	BMP2	bone morphogenetic protein 2
-2.40	0.02	Secreted	VEGE	vascular endothelial growth factor
-7.69	0.01	Secreted	EREG	epiregulin
-3.19	0.05	Secreted	ANGPTL6	angiopoietin-like 6
5.51	0.03	Secreted	ECGF1	endothelial cell growth factor 1
4.26	0.04	Secreted	CXCL12	chemokine ligand 12 (stromal cell-derived factor 1)
-30.96	0.05	Secreted	APOD DEER4	defensin beta 4
-25.77	0.00	Secreted	CCL27	chemokine (C-C motif) ligand 27
-3.79	0.02	Secreted	IL7	interleukin 7
2.41	0.02	Secreted	PDGFA	platelet-derived growth factor alpha polypeptide

Fig. 7 Activation and differentiation related genes. Fold changes, *P*-values, biological functions, gene symbols and unigene comments for genes implicated in keratinocyte activation and differentiation are shown.

complex, PARD and CDC42 are down-regulated in chronic wounds when compared to healthy skin.

Taken together, data obtained from microarray analysis indicate deregulation of early and late differentiation markers, aberrant cornified envelope assembly and deregulation of TJ molecules. This suggests a possible loss of barrier function in the epidermis of venous ulcers.

Keratinocyte differentiation: regulators

Microarray analyses revealed down-regulation of kuppel-like factor (KLF4), transcription factor, important for the establishment of skin barrier function as well as cross-linking of cornified envelope proteins [7, 33]. Furthermore, up-regulation of phospholipase D2





Filaggrin

Fig. 8 Keratinocyte differentiation markers are deregulated in venous ulcers. Immunofluorescence staining of skin specimens deriving from venous ulcers with K10, involucrin and filaggrin-specific antibodies show increased involucrin expression while K10 and filaggrin are barely detected. Scale bar 50 μm .

(PLD2) but not phospholipase D1 (PLD1) was found. The activation of these regulators has been implicated in late keratinocyte differentiation [34]. The Notch signalling pathway has been shown to play a role in defining different steps of keratinocyte differentiation [35, 36]. We have found Manic Fringe (MFNG) to be up-regulated and NOTCH2 to be down-regulated. Taken together, these data demonstrate deregulation of molecules that govern both early and terminal stages of differentiation.

Adhesion molecules of differentiating keratinocytes

In addition to changes in TJ expression, we observed a deregulation of several genes coding for proteins of the desmosomal complex in venous ulcers. Among desmosomal cadherins, desmocollin 2 (DSC2) and desmoglein 3 (DSG3) were up-regulated whereas desmocollin 3 (DSC3) and desmoglein 2 (DSG2) were down-regulated. Two other desmosomal molecules, desmoplakin (DP) and plakophilin 2 (PKP2) were also down-regulated in venous ulcers. To confirm the microarray data we stained healthy skin and skin specimens derived from venous ulcers with DSG2, DSG3 and DP-specific antibodies. Staining with DSG3 and DSC2 showed





increased signal throughout the epidermis of venous ulcers while signal of DP was decreased thus confirming deregulation of desmosomal proteins (Fig. 9).

Discussion

In this paper we present comprehensive analyses of the pathogenesis of non-healing edges of venous ulcers using transcriptional profiling, real-time PCR and immunohistochemistry. We found that hyperproliferation of keratinocytes in the epidermis of non-healing edges is, in part, due to a loss of a cell cycle control and incomplete activation. Furthermore, we found deregulation of early and late differentiation markers, as well as regulators of this processes, coupled with aberrant cornified envelope assembly and deregulation of TJ and desmosomal molecules. Taken together. data obtained from this study suggest that keratinocytes at the non-healing edges of venous ulcers are not capable of accomplishing either of two main processes in skin homeostasis: proliferation and differentiation.

In healthy skin, basal epidermal keratinocytes proliferate and, as they exit the basal cell compartment, they commit to a differentiation program. Keratinocyte differentiation requires DNA degradation, nuclear destruction and substantial proteolytic activity and leads to cell death resulting in the formation of a cornified layer and subsequently desquamation of dead cells. Our previous findings show that epidermis of chronic wounds is hyperproliferative with mitotically active cells present in suprabasal cell layers. These findings, coupled with the presence of the nuclei in a very thick cornified layer, suggest aberrant activation and incomplete differentiation of keratinocytes in chronic wounds.

When a wound occurs, keratinocytes at the wound edge become activated and start to express activation markers, keratins 6, 16 and 17. Keratinocytes from the non-healing edge of venous ulcers show a similar expression pattern. Although, the expression of K17 on microarrays showed less than a two fold increase, real-time PCR and immunohistochemistry confirmed robust induction. Keratins belong to the small group of genes that are highly expressed, thus exceeding a linear range of hybridization, leading to variable microarray readings [37–39]. Nevertheless, K17 was induced along with keratins K6 and K16, suggesting that initial activation process takes place in venous ulcers. In addition, it has been shown that pro-inflmmatory signals, including tumour necrosis factor- α (TNF- α), IL-1 and interferon- γ (IFN- γ) induce expression of these genes [40–43]. Thus, their induction is consistent with prolonged inflammation found in chronic wounds [44, 45].

We have shown previously that non-healing edge keratinocytes are marked by induction of c-myc and nuclear presence of β-catenin, leading to increased proliferation and inhibition of migration [9]. Data collected in this study further expands and confirms previous findings. Promotion of G1/S and G2/M cell cycle transitions in venous ulcers environment and loss of cell cycle control coupled with c-myc induction and keratinocytes activation may lead to a hyperproliferative phenotype. However, further conformation would require evaluation at the protein level, including posttranslation modifications and phosphorylation in particular. On the other hand, the loss of cell cycle control is not complete and some factors, like cyclin D1 and EIF4E, usually overexpressed during tumourigenesis [46] were down-regulated in venous ulcers. MFNG expression is restricted to proliferative basal layer during embryonic epidermal stratification [36], and up-regulation of MFNG in non-healing edges coupled with the presence of mitotically active cells in suprabasal layers may suggest its possible role in the induction of keratinocyte proliferation. We found down-regulation of IL-6 expression in non-healing edges of venous ulcers, which is consistent with findings in IL-deficient mice (interleukin-6 knockout (IL-6KO)) that display delayed wound closure [47]. SDF-1 α from keratinocytes and myofibroblasts has been shown to participate in homing of endothelial progenitor cells to the wound site. The db/db mouse wound model exhibit decreased expression of SDF-1 α , suggesting possible decrease in diabetic foot ulcers [48, 49]. Interestingly, we found SDF1 α up-regulated in venous ulcers. This may indicate that changes in SDF-1 α expression may be associated specifically with diabetes rather than with impaired healing in general.

Keratinocyte early differentiation markers K1/K10 were downregulated in our experiment, which is consistent with previous findings and further validates our microarray analyses [50]. Up-regulation of TGM1, an enzyme involved in the initial cross linking during cornification process along with IVL, which is a major early cross-linked component of cornified envelope as well as S100A7 and SPRR1A, SPRR1B, SPRR2B, SPRR3, indicates improper cornified envelope assembly [51]. FLG, one of the key proteins that facilitate terminal differentiation of the epidermis and formation of the skin barrier, was found down-regulated. It has been shown that once keratinocytes process pro-FLG into FLG they undergo specific changes that mark terminal differentiation [52], and that perhaps this process demarcates the 'line of regenerative potency' among the population of differentiating keratinocytes [53]. Down-regulation of FLG in venous ulcer coupled with deregulation of other keratinocyte differentiation markers suggests that keratinocytes at the edge of nonhealing venous ulcers start to differentiate but are not capable of completing the process. In support of this finding, we also detected down-regulation of PLD1 in venous ulcers. It has been shown that during keratinocyte differentiation PLD1 mRNA levels increase [54]. Furthermore, the highest levels of PLD1 expression were found in the more differentiated lavers of the epidermis, with negligible expression in basal keratinocytes [55]. Down-regulation of PLD1 expression in venous ulcers may indicate some form of de-differentiation and supports the notion that these keratinocytes do not execute the process to its completion. Similarly, we also found APOD (recently associated with differentiating keratinocytes) to be down-regulated in our venous ulcers [29].

Similar to findings of deregulation of differentiation markers and molecules that participate in this process and consistent with morphology of epidermis in venous ulcers, we also found deregulation of signalling molecules that control the process of differentiation. The overall findings are that the regulatory signals are sending 'mixed messages' to the cells leading to deregulation of the process. In differentiating epidermal keratinocytes, BMPs stimulate expression of K1, IVL and distal-less homeobox 3 (DIx3) transcription factor, suggesting that these molecules may be targets for BMP signalling [56, 57]. It's been shown that BMP2 inhibits keratinocyte proliferation and promotes their terminal differentiation [58]. Thus, down-regulation of BMP2 in venous ulcers may account for keratinocyte hyperproliferation and deregulation of terminal differentiation. In addition, down- regulation of KLF4, a transcription factor highly expressed in differentiating layers of epidermis important for the establishment of skin barrier function and expression/cross-linking of cornified envelope proteins, further confirms improper regulation of differentiation process in venous ulcers [7, 33].

Another interesting observation is the down-regulation of $I\kappa B\alpha$ expression in venous ulcers, which supports previous findings of prolonged inflammation. It has been shown that keratinocytes in $I\kappa B\alpha$ -deficient mice are highly proliferative with deregulated epidermal differentiation [59], thus exhibiting phenotype similar to that of a non-healing epidermis of venous ulcers. Changes in expression of genes participating in regulation of keratinocyte differentiation program contribute to abnormal keratinocyte differentiation.

Adhesion molecules exert a dynamic role in epidermal differentiation/stratification. Down-regulation of TJ proteins, particularly claudins suggest a loss of permeability barrier function of the epidermis in our venous ulcer samples. This is corroborated by the inability of claudins to prevent TJ formation in KO mice, as well as a complete alteration in their function [60, 61]. Recent papers suggest that activity of complex Par3, Par6, atypical PKC-iota and CDC42 in granular layer of epidermis is necessary for TJ formation and keratinocyte differentiation [62]. Furthermore during calcium-induced differentiation of keratinocytes, atypical PARD was necessary for establishment of barrier formation. This complex had characteristic re-distribution during wound healing and it may also be an endogenous regulator of asymmetric cell division of basal keratinocytes. Asymmetric cell division, on other hand, promotes stratification and wound healing in the skin by keeping balance between proliferation and differentiation [30, 63]. Downregulation of atypical PARD and CDC42 suggests loss of cell polarity further suggesting a loss of balance between keratinocyte

polarity further suggesting a loss of balance between keratinocyte proliferation and differentiation and deregulation of TJ formation. Further investigation is necessary to analyse the exact localization of the polarity complex as well as TJ in hyperproliferative epidermis of venous ulcers.

We also observed deregulation of desmosomal components in the non-healing edges of venous ulcers. In the normal epidermis, DSC2 and DSG2 are found highly expressed in the proliferative basal layers of the epidermis. We recently showed that DSG2 plays a role in keratinocyte cell proliferation and survival [64]. Therefore a suppression of DSG2 expression may alter keratinocyte proliferation in venous ulcers. DSG3 expression, on the other hand, extends from the basal to spinous layers with intensity decreasing with differentiation. In venous ulcers, DSG3 was up-regulated and expressed throughout hyperproliferative epidermis, which is in agreement with previously publish data obtained from murine models, suggesting that differential expression of desmosomal proteins within the epidermis participate in the regulation of the tissue proliferation and differentiation [64–68]. When DSG3 was overexpressed under the control of K1 promoter in the suprabasal epidermis of transgenic mice, histological analysis of the skin revealed a hyperproliferative epidermis with hyper- and parakeratosis, along with abnormal epidermal differentiation [65]. Interestingly, despite the high expression of DSG3 and DSC2 in venous ulcers, expression of their associated plaque protein DP was greatly suppressed. This apparent lack of association between DSG3 and DP has been shown in DP RNAitreated cells [69]. Similar to that observed here in venous ulcers, reduction of DP expression in a mild form of striate palmoplantar keratoderma also results in hyperproliferation and hyperkeratosis [70] further supporting a role for DP in regulating keratinocyte proliferation and differentiation. These data suggest that deregulation and atypical expression of desmosomal components may play a role in altered keratinocyte differentiation.

In the future, several different comparative genomics studies would prove very useful in delineating molecular pathogenesis of chronic wounds. For example, comparing transcriptional profiles of non-healing edges of chronic to acute wounds in different stages would identify specific wound-healing genes which contribute to non-healing phenotype. In addition, comparing transcriptional profiles of non-healing edges from venous to diabetic foot ulcers or pressure ulcers will identify common pathways that lead to non-healing phenotype in majority of chronic wounds. Proposed experiments underscore technical challenges in this field. Specifically, selection of controls is fundamental to the outcome of the data. Our laboratory has worked over the years to establish how variable human samples actually show consistent expression profiles [37] and, further, how to standardize the wound biopsy from patient to patient [10]. To address the issue of mixed cell populations in our skin samples. mRNA levels of abundantly expressed genes specific for two major cell types: perlecan and vimentin (fibroblasts) and stratifin and junctional plakoglobin (keratinocytes) were compared using microarrays. The signal intensity levels correlate to the hybridization signal intensity of vimentin, perlecan, stratifin and junctional plakoglobin and are a direct measure of the mRNA levels in each biopsy. All biopsies show consistent levels of expression for perlecan, stratifin and junctional plakoglobin suggesting that both the keratinocytes and fibroblasts are present at the consistent numbers in our venous ulcer biopsies [10]. Evaluations of microarray findings were performed on biopsies from venous ulcers of subsequent set of patients, which further documents the validity of the data obtained. In addition, technical aspects of harvesting the tissue, such as lidocaine injection, presence of infection, could be perceived as factors that may influence the data outcome. There is evidence in literature that lidocaine decreases proliferation of cultured human keratinocytes [71]. However, samples for this study were harvested within 30 min. after the lidocaine injection and immediately processed for RNA purification. Therefore, the lidocaine did not affect the outcome. In addition, we have established that specimens harvested using this procedure exhibit marked hyperproliferation [9, 10] which was further confirmed by microarrays presented in this manuscript.

Our data indicate that keratinocytes in venous ulcers initiate differentiation, carry out atypical cornified envelope assembly, and proceed towards terminal differentiation, but fail to completely execute the terminal process of differentiation and barrier formation. Most of the current understanding of the pathophysiology of venous ulcers comes from the tissue level [72], but our data expands on previous work to examine why a venous wound might not heal on a cellular level. For a physician, the implications of this research provide a rational biologic basis for debridement of venous ulcers to remove the skin cells that do not have the ability to migrate properly, leaving those that do.

Taken together, the data collected from this microarray study suggest that, on the one hand, keratinocytes at the non-healing edges of venous ulcers express activation markers, show deregulation of a cell cycle associated genes, and loss of cell cycle control. On the other hand, they show deregulation of early and late differentiation markers, TJ and desmosomal proteins as well as regulators of differentiation and perform aberrant cornified envelope assembly. Thus, keratinocytes at the non-healing edges of venous ulcers do not successfully complete either of the two possible pathways in a proper manner: proliferation or differentiation. Instead, keratinocytes are constantly trying, without success, to achieve either of the two processes.

Acknowledgements

Our research is supported by the NIH grants NR08029 (MT-C), DK59424 (HB), LM008443 (HB).

References

- Valencia IC, Falabella A, Kirsner RS, Eaglstein WH. Chronic venous insufficiency and venous leg ulceration. J Am Acad Dermatol. 2001; 44: 401–21.
- Abbade LP, Lastoria S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol. 2005; 44: 449–56.
- Brem H, Kirsner RS, Falanga V. Protocol for the successful treatment of venous ulcers. *Am J Surg.* 2004; 188: 1–8.
- 4. Etufugh CN, Phillips TJ. Venous ulcers. *Clin Dermatol.* 2007; 25: 121–30.
- Olin JW, Beusterien KM, Childs MB, Seavey C, McHugh L, Griffiths RI. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med. 1999; 4: 1–7
- Falanga V, Margolis D, Alvarez O, Auletta M, Maggiacomo F, Altman M, Jensen J, Sabolinski M, Hardin-Young J. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermato. 1998: 134: 293–300.
- Bazzoni G, Dejana E. Keratinocyte junctions and the epidermal barrier: how to make a skin-tight dress. *J Cell Biol.* 2002; 156: 947–9
- Tomic-Canic M, Komine M, Freedberg IM, Blumenberg M. Epidermal signal transduction and transcription factor activation in activated keratinocytes. *J Dermatol Sci.* 1998; 17: 167–81
- Stojadinovic O, Brem H, Vouthounis C, Lee B, Fallon J, Stallcup M, Merchant A, Galiano RD, Tomic-Canic M. Molecular pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of epithelialization and wound healing. *Am J Pathol.* 2005; 167: 59–69.
- Brem H, Stojadinovic O, Diegelmann RF, Entero H, Lee B, Pastar I, Golinko M, Rosenberg H, Tomic-Canic M. Molecular markers in patients with chronic wounds to guide surgical debridement. *Mol Med.* 2007; 13: 30–9.
- Quackenbush J. Microarray analysis and tumor classification. *N Engl J* Med.2006; 354: 2463–72.
- Adler AS, Chang HY. From description to causality: mechanisms of gene expression signatures in cancer. *Cell Cycle.* 2006; 5: 1148–51.
- 13. Riss J, Khanna C, Koo S, Chandramouli GV, Yang HH, Hu Y, Kleiner DE,

Rosenwald A, Schaefer CF, Ben-Sasson SA, Yang L, Powell J, Kane DW, Star RA, Aprelikova O, Bauer K, Vasselli JR, Maranchie JK, Kohn KW, Buetow KH, Linehan WM, Weinstein JN, Lee MP, Klausner RD, Barrett JC. Cancers as wounds that do not heal: differences and similarities between renal regeneration/ repair and renal cell carcinoma. *Cancer Res.* 2006; 66: 7216–24

- Sato T, Konomi K, Yamasaki S, Aratani S, Tsuchimochi, K Yokouchi M, Masuko-Hongo K, Yagishita N, Nakamura H, Komiya S, Beppu M, Aoki H, Nishioka K, Nakajima T. Comparative analysis of gene expression profiles in intact and damaged regions of human osteoarthritic cartilage. Arthritis Rheum. 2006; 54: 808–17
- Grose R. Common ground in the transcriptional profiles of wounds and tumors. *Genome Biol.* 2004; 5: 228.
- Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C, Wang E, Marincola FM, Stroncek DF. Gene expression profiling of cutaneous wound healing. J Transl Med. 2007; 5: 11.
- 17. **Tomic-Canic M, Brem H.** Gene array technology and pathogenesis of chronic wounds. *Am J Surg.* 2004; 188: 67–72.
- Cole J, Tsou R, Wallace K, Gibran N, Isik F. Early gene expression profile of human skin to injury using high-density cDNA microarrays. *Wound Repair Regen*. 2001; 9: 360–70.
- Olson NE. The microarray data analysis process: from raw data to biological significance. *NeuroRx.* 2006; 3: 373–83.
- Stojadinovic O, Lee B, Vouthounis C, Vukelic S, Pastar I, Blumenberg M, Brem H, Tomic-Canic M. Novel genomic effects of glucocorticoids in epidermal keratinocytes: inhibition of apoptosis, interferon-gamma pathway, and wound healing along with promotion of terminal differentiation. J Biol Chem. 2007; 282: 4021–34.
- Dale BA, Holbrook KA, Kimball JR, Hoff M, Sun TT. Expression of epidermal keratins and filaggrin during human fetal skin development. *J Cell Biol.* 1985; 101: 1257–69.
- McGowan KM, Coulombe PA. Onset of keratin 17 expression coincides with the definition of major epithelial lineages during skin development. J Cell Biol. 1998; 143: 469–86.
- 23. Robson MC, Cooper DM, Aslam R, Gould LJ, Harding KG, Margolis DJ, Ochs DE,

Serena TE, Snyder RJ, Steed DL, Thomas DR, Wiersma-Bryant L. Guidelines for the treatment of venous ulcers. *Wound Repair Regen.*, 2006; 14: 649–62.

- 24. Sherr CJ. Cancer cell cycles. *Science*. 1996; 274: 1672–7.
- Weinberg RA. The retinoblastoma protein and cell cycle control. *Cell*, 1995; 81: 323–30.
- Oike Y, Yasunaga K, Ito Y, Matsumoto S, Maekawa H, Morisada T, Arai F, Nakagata N, Takeya M, Masuho Y, Suda T. Angiopoietin-related growth factor (AGF) promotes epidermal proliferation, remodeling, and regeneration. *Proc Natl* Acad Sci USA. 2003; 100: 9494–9.
- Haider AS, Peters SB, Kaporis H, Cardinale I, Fei J, Ott J, Blumenberg M, Bowcock AM, Krueger JG, Carucci JA. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol. 2006; 126: 869–81
- Telgenhoff D, Shroot B. Cellular senescence mechanisms in chronic wound healing. *Cell Death Differ*. 2005; 12: 695–8.
- Radoja N, Gazel A, Banno T, Yano S, Blumenberg M. Transcriptional profiling of epidermal differentiation. *Physiol Genomics*. 2006; 27: 65–78.
- 30. **Denning MF.** Tightening the epidermal barrier with atypical PKCs. *J Invest Dermatol.* 2007; 127: 742–4.
- Brandner JM, Kief S, Wladykowski E, Houdek P, Moll I. Tight junction proteins in the skin. *Skin Pharmacol Physiol.* 2006; 19: 71–7.
- Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. *Am J Physiol Cell Physiol*. 2004; 286: C1213–28.
 Segre J. Complex redundancy to build a simple epidermal permeability barrier.
- Curr Opin Cell Biol. 2003; 15: 776–82.
 34. Jung EM, Betancourt-Calle S, Mann-Blakeney R, Griner RD, Bollinger W. Sustained phospholipase D activation is associated with keratinocyte differentiation. Carcinogenesis. 1999; 20: 569–76.
- Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, Aster JC, Krishna S, Metzger D, Chambon P, Miele L, Aguet M, Radtke F, Dotto GP. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. *EMBO J.* 2001; 20: 3427–36.

- Thelu J, Viallet JP, Dhouailly D. Differential expression pattern of the three Fringe genes is associated with epidermal differentiation. J Invest Dermatol 1998; 111: 903–6.
- Gazel A, Ramphal P, Rosdy M, De Wever B, Tornier C, Hosein N, Lee B, Tomic-Canic M, Blumenberg M. Transcriptional profiling of epidermal keratinocytes: comparison of genes expressed in skin, cultured keratinocytes, and reconstituted epidermis, using large DNA microarrays. J Invest Dermatol. 2003; 121: 1459–68.
- Banno T, Gazel A, Blumenberg M. Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes. J Biol Chem. 2005; 280: 18973–80.
- Tomic-Canic M, Blumenberg M. Gene profiling: implications in dermatology. *Future Drugs*. 2007; 2: 763–8.
- Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem. 2004; 279: 32633–42.
- Banno T, Adachi M, Mukkamala L, Blumenberg M. Unique keratinocyte-specific effects of interferon-gamma that protect skin from viruses, identified using transcriptional profiling. *Antivir Ther.* 2003; 8: 541–54.
- Komine M, Rao LS, Freedberg IM, Simon M, Milisavljevic V, Blumenberg M. Interleukin-1 induces transcription of keratin K6 in human epidermal keratinocytes. *J Invest Dermatol.* 2001; 116: 330–8.
- Komine M, Freedberg IM, Blumenberg M. Regulation of epidermal expression of keratin K17 in inflammatory skin diseases. *J Invest Dermatol.* 1996; 107: 569–75.
- Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. *Front Biosci.* 2004; 9: 283–9.
- Harding KG, Moore K, Phillips TJ. Wound chronicity and fibroblast senescence – implications for treatment. *Int Wound J.* 2005; 2: 364–8.
- Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierre M, Borden KL. elF4E promotes nuclear export of cyclin D1 mRNAs *via* an element in the 3'UTR. *J Cell Biol.* 2005; 169: 245–56.
- Gallucci RM, Lee EG, Tomasek JJ. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. *J Invest Dermatol.* 2006; 126: 561–8.

- Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, Buerk DG, Nedeau A, Thom SR, Velazquez OC. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1alpha. J Clin Invest. 2007; 117: 1249–59.
- Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. *J Clin Invest*. 2007; 117: 1219–22.
- Galkowska H, Olszewsk WL, Wojewodzka U, Mijal J, Filipiuk E. Expression of apoptosis- and cell cycle-related proteins in epidermis of venous leg and diabetic foot ulcers. *Surgery.* 2003; 134: 213–20.
- Steinert PM, Marekov LN. Direct evidence that involucrin is a major early isopeptide cross-linked component of the keratinocyte cornified cell envelope. J Biol Chem. 1997; 272: 2021–30.
- Presland RB, Kuechle MK, Lewis SP, Fleckman P, Dale BA. Regulated expression of human filaggrin in keratinocytes results in cytoskeletal disruption, loss of cell-cell adhesion, and cell cycle arrest. *Exp Cell Res.* 2001; 270: 199–213.
- Morasso MI, Tomic-Canic M. Epidermal stem cells: the cradle of epidermal determination, differentiation and wound healing. *Biol Cell.* 2005; 97: 173–83.
- Nakashima S, Nozawa Y. Possible role of phospholipase D in cellular differentiation and apoptosis. *Chem Phys Lipids.* 1999; 98: 153–64.
- Griner RD, Qin F, Jung E, Sue-Ling CK, Crawford KB, Mann-Blakeney R, Bollag RJ, Bollag WB. 1,25-dihydroxyvitamin D3 induces phospholipase D-1 expression in primary mouse epidermal keratinocytes. J Biol Chem. 1999; 274: 4663–70.
- Botchkarev VA. Bone morphogenetic proteins and their antagonists in skin and hair follicle biology. *J Invest Dermatol.* 2003; 120: 36–47.
- Park GT, Morasso MI. Regulation of the DIx3 homeobox gene upon differentiation of mouse keratinocytes. J Biol Chem. 1999; 274: 26599–608.
- Gosselet FP, Magnaldo T, Culerrier RM, Sarasin A, Ehrhart JC. BMP2 and BMP6 control p57(Kip2) expression and cell growth arrest/terminal differentiation in normal primary human epidermal keratinocytes. *Cell Signal.* 2007; 19: 731–9.
- Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, Sanjo H, Yoshikawa K, Terada N, Akira S. Limb and skin abnormalities in mice lacking IKKalpha. *Science.* 1999; 284: 313–6.

- Pummi K, Malminen M, Aho H, Karvonen SL, Peltonen J, Peltonen S. Epidermal tight junctions: ZO-1 and occludin are expressed in mature, developing, and affected skin and *in vitro* differentiating keratinocytes. J Invest Dermatol. 2001; 117: 1050–8.
- Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, Noda T, Kubo A, Tsukita S. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol. 2002; 156: 1099–111.
- Helfrich I, Schmitz A, Zigrino P, Michels C, Haase I, Ie Bivic A, Leitges M, Niessen CM. Role of aPKC isoforms and their binding partners Par3 and Par6 in epidermal barrier formation. J Invest Dermatol. 2007; 127: 782–91.
- Lechler T, Fuchs E. Asymmetric cell divisions promote stratification and differentiation of mammalian skin. *Nature*. 2005; 437: 275–80.
- Brennan D, Hu Y, Joubeh S, Choi Y, Whitaker-Menezes D, O'Brien T, Uitto J, Rodeck U, Mahoney MG. Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosisresistant phenotype to keratinocytes J Cell Sci. 2007; 120: 758–71.
- Merritt AJ, Berika MY, Zhai W, Kirk SE, Ji B, Hardman MJ, Garrod DR. Suprabasal desmoglein 3 expression in the epidermis of transgenic mice results in hyperproliferation and abnormal differentiation. *Mol Cell Biol.* 2002; 22: 5846–58.
- Hardman MJ, Liu K, Avilion AA, Merritt A, Brennan K, Garrod DR, Byrne C. Desmosomal cadherin misexpression alters beta-catenin stability and epidermal differentiation. *Mol Cell Biol.* 2005; 25: 969–78.
- Smith C, Zhu K, Merritt A, Picton R, Youngs D, Garrod D, Chidgey M. Regulation of desmocollin gene expression in the epidermis: CCAAT/enhancerbinding proteins modulate early and late events in keratinocyte differentiation. *Biochem J.* 2004; 380: 757–65.
- Garrod D, Chidgey M, Nort AH. Desmosomes: differentiation, development, dynamics and disease. *Curr Opin Cell Biol.* 1996; 8: 670–8.
- Wan H, South AP, Hart IR. Increased keratinocyte proliferation initiated through downregulation of desmoplakin by RNA interference. *Exp Cell Res.* 2007; 313: 2336–44.
- Wan H, Dopping-Hepenstal PJ, Gratian MJ, Stone MG, Zhu G, Purkis PE, South AP, Keane F, Armstrong DK, Buxton RS,

McGrath JA, Eady RA. Striate palmoplantar keratoderma arising from desmoplakin and desmoglein 1 mutations is associated with contrasting perturbations of desmosomes and the keratin filament network. *Br J Dermatol.* 2004; 150: 878–91.

- Martinsson TA, Haegerstrand A, Dalsgaard CJ. Ropivacaine and lidocaine inhibit proliferation of non-transformed cultured adult human fibroblasts, endothelial cells and keratinocytes. *Agents Actions.* 1993; 40: 78–85.
- Labropoulos N, Patel PJ, Tiongson JE, Pryor L, Leon Jr. LR, Tassiopoulos AK. Patterns of venous reflux and obstruction in patients with skin damage due to chronic venous disease. Vasc Endovascular Surg. 2007; 41: 33–40.